242 results on '"Sung Ho Her"'
Search Results
2. Admission serum potassium levels and prognosis of vasospastic angina
- Author
-
Won-Woo Seo, Sang-Ho Jo, Sung Eun Kim, Hyun-Jin Kim, Seung Hwan Han, Kwan Yong Lee, Sung Ho Her, Min-Ho Lee, Seong-Sik Cho, Hack-Lyoung Kim, and Sang Hong Baek
- Subjects
Medicine ,Science - Abstract
Abstract Hypokalemia is a common electrolyte disturbance and is related to poor prognosis in patients with cardiovascular disease. However, the role of hypokalemia in patients with vasospastic angina (VSA) has not yet been studied. The present study enrolled 1454 patients diagnosed with VSA according to ergonovine provocation test results and available admission serum potassium data. The primary outcome was a composite of cardiac death, acute coronary syndrome, and new-onset life-threatening arrhythmia. Based on a hypokalemia definition as serum potassium concentration ≤ 3.5 mEq/L, the hypokalaemia group included 70 patients (4.8%). The median potassium levels were 3.4 mEq/L [interquartile range (IQR) 3.3–3.5] in the hypokalemia group and 4.1 mEq/L (IQR 3.9–4.3) in the no-hypokalemia group. The median follow-up duration was 764 days. Primary outcomes occurred in seven patients (10.0%) in the hypokalemia group and 51 patients (3.7%) in the no-hypokalemia group. The Kaplan–Meier analysis showed a higher cumulative incidence of primary outcomes in the hypokalemia group compared to that in the no-hypokalemia group (log-rank P = 0.014). Multivariate Cox regression analysis also showed that hypokalemia was an independent predictor of primary outcomes. In conclusion, hypokalemia at admission was associated with adverse clinical outcomes in VSA. more...
- Published
- 2021
- Full Text
- View/download PDF
Catalog
3. Comparison of calcium-channel blockers for long-term clinical outcomes in patients with vasospastic angina
- Author
-
Sung Eun Kim, Sang-Ho Jo, Seung Hwan Han, Kwan Yong Lee, Sung Ho Her, Min-Ho Lee, Won-Woo Seo, Seong-Sik Cho, and Sang Hong Baek
- Subjects
coronary vasospasm ,calcium channel blockers ,patient outcome assessment ,Medicine - Abstract
Background/Aims Calcium channel blockers (CCBs) are the most widely prescribed medication for patients with vasospastic angina (VA). However, few studies have compared the prognosis of VA patients who are prescribed different CCBs. Methods We enrolled 2,960 patients who received provocation test prospectively in 11 university hospitals in Korea. We divided 1,586 patients received four major CCBs into two groups: a first generation CCB (diltiazem and nifedipine) group and a second generation CCB (amlodipine and benidipine) group. Primary outcome was time to events of composite of death from any cause, acute coronary syndrome (ACS) and symptomatic arrhythmia during 3-year follow-up. We also compared the effect of each CCB on the control of angina symptoms. Results There was no difference of the primary outcome among the two groups with a cumulative incidence rate of 5.4%, 2.9%, and a person-month incidence rate of 2.33 and 1.26, respectively (hazard ratio [HR], 0.54; 95% confidence interval [CI], 0.25 to 1.17; p = 0.120, as reference with the 1st generation CCBs). The incidence of ACS was significantly lower in 2nd generation CCBs group with a person-month incidence rate of 1.66 vs. 0.35 (HR, 0.22; 95% CI, 0.05 to 0.89; p = 0.034). Use of benidipine showed a significant better control of angina symptom compared with diltiazem for 3 years (odds ratio, 0.17; 95% CI, 0.09 to 0.32; p < 0.0001 at 3rd year). Conclusions The first and second generation CCB groups did not differ in terms of composite outcome occurrence. However, the ACS incidence rate was significantly lower in the users of the 2nd generation CCBs. more...
- Published
- 2021
- Full Text
- View/download PDF
4. Kearns-sayre Syndrome Treated with Permanent Pacemaker Insertion for Complete Atrioventricular Block
- Author
-
Eun Hye Park, Sung Ho Her, Myung A Ha, Hyo Suk Kim, and Jae Hyuk Jang
- Subjects
complete av block ,kearns-sayre syndrome ,permanent pacemaker ,Medicine (General) ,R5-920 - Abstract
Kearns-Sayre syndrome (KSS) is a rare multisystem mitochondrial disorder associated with progressive external ophthalmoplegia, atypical pigmentary degeneration of the retina, and complete heart block. KSS can lead to a risk of sudden death because of the potential progression of conduction abnormalities such as right or left bundle branch block or complete atrioventricular (AV) block. Here we describe the case of a KSS patient with type I diabetes who experienced syncope in the presence of complete AV block, confirmed by muscular biopsy. more...
- Published
- 2017
- Full Text
- View/download PDF
5. Impact of diabetes mellitus in patients undergoing contemporary percutaneous coronary intervention: Results from a Korean nationwide study.
- Author
-
Yujin Yang, Gyung-Min Park, Seungbong Han, Yong-Giun Kim, Jon Suh, Hyun Woo Park, Ki-Bum Won, Soe Hee Ann, Shin-Jae Kim, Dae-Won Kim, Mahn-Won Park, Sung Ho Her, and Sang-Gon Lee
- Subjects
Medicine ,Science - Abstract
ObjectivesDespite an obvious improvement in the treatment of coronary artery disease (CAD) and survival rate of patients with CAD during recent decades, diabetes mellitus (DM) is still considered a risk factor of adverse clinical outcomes in these patients. Therefore, we sought to evaluate the clinical implications of DM in patients with CAD who underwent contemporary percutaneous coronary intervention (PCI).MethodsBased on the National Health Insurance claims data in South Korea, patients aged 18 years or older who had undergone PCI for the diagnosis of CAD between 2011 and 2015 were analyzed. Patients were classified into the DM (n = 26,872) and non-DM (n = 54,243) groups. The primary endpoint was all-cause mortality, and it was compared between the two groups via a propensity score matching analysis.ResultsThe study population was categorized as patients with angina (n = 49,228) or acute myocardial infarction (AMI, n = 31,887). The study population had a median follow-up of 2.1 years (interquartile range, 1.1-3.2). After the propensity score matching analysis, 8,157 and 4,266 pairs of patients with angina and AMI were identified, respectively. In the matched angina group, the incidence of all-cause death was significantly higher in patients with DM (adjusted hazard ratio [aHR]: 1.30; 95% confidence interval [CI]: 1.16-1.47; pConclusionsIn patients undergoing contemporary PCI in Korea, the presence of DM was associated with poorer clinical outcomes. more...
- Published
- 2018
- Full Text
- View/download PDF
6. Moderate-intensity versus high-intensity statin therapy in Korean patients with angina undergoing percutaneous coronary intervention with drug-eluting stents: A propensity-score matching analysis.
- Author
-
Mahn-Won Park, Gyung-Min Park, Seungbong Han, Yujin Yang, Yong-Giun Kim, Jae-Hyung Roh, Hyun Woo Park, Jon Suh, Young-Rak Cho, Ki-Bum Won, Soe Hee Ann, Shin-Jae Kim, Dae-Won Kim, Sung Ho Her, and Sang-Gon Lee more...
- Subjects
Medicine ,Science - Abstract
ObjectivesIt is unclear whether high-intensity statin therapy provides incremental clinical benefits over moderate-intensity statin therapy in Asian patients with angina. This study sought to compare the clinical outcomes of moderate- and high-intensity statin therapies in patients undergoing percutaneous coronary intervention (PCI) for angina in Korean patients.MethodsBased on the national health insurance claims data in South Korea, patients aged 18 years or older without a known history of coronary artery disease, who underwent PCI with drug-eluting stents due to angina between 2011 and 2015, were enrolled. According to the intensity of statin therapy, patients were categorized into moderate-intensity statin therapy (n = 23,863) and high-intensity statin therapy (n = 9,073) groups. The primary endpoint, defined as a composite of all-cause death and myocardial infarction, was compared between the two groups using a propensity-score matching analysis.ResultsDuring the follow-up period (median, 2.0 years; interquartile range, 1.1-3.1), 1,572 patients had 1,367 deaths and 242 myocardial infarctions. After propensity-score matching, there were 8,939 matched pairs. There was no significant difference in the incidence of the primary endpoint between the two groups (adjusted hazard ratio of high-intensity statin therapy, 1.093; 95% confidence interval: 0.950-1.259; p = 0.212).ConclusionsIn Korean patients undergoing PCI with drug-eluting stents for angina, the high-intensity statin therapy did not provide additional clinical benefits over the moderate-intensity statin therapy. more...
- Published
- 2018
- Full Text
- View/download PDF
7. Comparison of 6-Month and Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Biodegradable Polymer Everolimus-Eluting Stent
- Author
-
Yong-Hoon Yoon, Gyung-Min Park, Jae-Hyung Roh, Sung-Ho Her, Seong-Hoon Lim, Tae Soo Kang, Seung Jin Lee, Jang-Whan Bae, WoongGil Choi, Yong-Mo Yang, Junghee Kim, Yu Jeong Choi, Si Wan Choi, and Jae-Hwan Lee more...
- Subjects
Article Subject ,Cardiology and Cardiovascular Medicine - Abstract
Background. The optimal duration of dual antiplatelet therapy (DAPT) after biodegradable-polymer (BP) everolimus-eluting stent (EES) implantation remains uncertain. Methods. This study analyzed 793 patients who underwent percutaneous coronary intervention (PCI) with BP-EES in 10 cardiovascular centers in Korea between July 2016 and January 2018. Using the prescription data at 6 months post-PCI, we divided these patients into two groups, namely, short-DAPT and prolonged-DAPT groups, which underwent DAPT for 6 and > 6 months of PCI, respectively. The primary endpoint, which included mortality, myocardial infarction, or target-vessel revascularization at 2 years, was compared by propensity score (PS) matching between the two groups. Results. Out of the 793 patients, 283 matched pairs were identified by PS matching. Out of this matched population, 405 (71.6%) patients had an acute coronary syndrome. The primary endpoint did not differ in 2 years between the short-DAPT and prolonged-DAPT groups (7.5% vs. 8.3%; hazard ratio, 0.87; 95% confidential interval, 0.47–1.60; P = 0.648 ). Likewise, no difference was found regarding mortality, cardiac mortality, myocardial infarction, target-lesion failure, target-vessel failure, and bleeding events defined by the Bleeding Academic Research Consortium and Thrombolysis In the Myocardial Infarction classification. Meanwhile, one patient in the short-DAPT group had definite stent thrombosis at 364 days post-PCI. Subgroup analysis showed that several anatomical and procedural factors were not significantly related to DAPT duration. Most patients (77.4%) in both groups were prescribed clopidogrel at discharge. Conclusions. In real-world patients undergoing PCI with BP-EES, the ischemic and bleeding endpoints demonstrated no difference between 6-month and prolonged (>6 months) DAPT. more...
- Published
- 2022
- Full Text
- View/download PDF
8. Effect of angiotensin receptor blocker dose in MI with preserved left ventricular systolic function
- Author
-
Hee-Yeol Kim, Jisu Mok, Jae-Young Kim, Doosoo Jeon, Sung-Ho Her, Mahn Won Park, Dong-Bin Kim, Chul-Su Park, Jong-Min Lee, Kiyuk Chang, Wook Sung Jung, and Yongkeun Ahn
- Subjects
Pharmacology ,Cardiology and Cardiovascular Medicine - Published
- 2023
- Full Text
- View/download PDF
9. Risk of cardiovascular disease according to gender and lifestyle behaviors in adults with depressive symptoms: a prospective UK Biobank study
- Author
-
Su Nam Lee, Jae-Seung Yun, Seung-Hyun Ko, Yu-Bae Ahn, Ki-Dong Yoo, Sung-Ho Her, Donggyu Moon, Sang-Hyuk Jung, Hong-Hee Won, and Dokyoon Kim
- Abstract
Depression is a well-known risk factor of cardiovascular disease (CVD). However, how the relationship of depressive symptoms and CVD changes with gender and healthy lifestyle has not been studied. Therefore, we investigated the association between depressive symptoms and CVD risk according to gender and lifestyle. The UK Biobank is a national prospective cohort study that recruited middle-aged participants between 2006 and 2010. Depressive symptoms were assessed by self-reported frequency of depressive mood using the 2-week recall method. Participants were classified as having low, moderate, high, or very high symptom level according to the number of days they felt depressed in a 2-week period. The primary outcome was incident CVD including coronary artery disease, ischemic stroke, hemorrhagic stroke, peripheral artery disease, atrial fibrillation/flutter, and heart failure. Participants reporting more depressive symptoms were younger and more likely to have comorbidities and unfavorable lifestyle behaviors. During a median follow-up of 8.9 years, 27,394 (6.3%) developed CVD. As the frequency of depressive symptoms increased, CVD risk also increased. After adjusting for multiple variables, CVD risk was 1.38-fold higher for subjects with very high depressive symptoms compared to those with low depressive symptoms. (HR 1.38, 95% CI 1.24–1.53, P more...
- Published
- 2023
- Full Text
- View/download PDF
10. TCTAP C-052 A Case of Successful Rotational Atherectomy in a Heavily Calcified, Uncrossable Chronic Total Occulsion Lesion
- Author
-
Jin Jung and Sung-Ho Her
- Subjects
Cardiology and Cardiovascular Medicine - Published
- 2022
- Full Text
- View/download PDF
11. Impact of diabetes mellitus on periprocedural and 18-month clinical outcomes in Korean patients requiring rotational atherectomy: results from the ROCK Registry
- Author
-
Su Nam Lee, Donggyu Moon, Sung-Ho Her, Won Young Jang, Keon-Woong Moon, Ki-Dong Yoo, Kyusup Lee, Jae Hwan Lee, Jang Hoon Lee, Sang Rok Lee, Seung-Whan Lee, Kyeong Ho Yun, Hyun-Jong Lee, and Ik Jun Choi more...
- Subjects
Atherectomy, Coronary ,Percutaneous Coronary Intervention ,Treatment Outcome ,Diabetes Mellitus ,Humans ,General Medicine ,Coronary Artery Disease ,Registries ,Coronary Angiography ,Vascular Calcification ,Retrospective Studies - Abstract
BACKGROUND: Diabetes mellitus (diabetes) increases the risk of severe coronary artery calcification, which increases the complexity of percutaneous coronary intervention requiring rotational atherectomy (RA) by interfering with lesion preparation, and limiting final stent expansion. OBJECTIVE: Investigate 30-day and 18-month clinical outcomes in patients with and without diabetes treated with percutaneous coronary intervention requiring RA. DESIGN: Medical record review SETTING: Multicenter registry in South Korea PATIENTS AND METHODS: The ROtational atherectomy in Calcified lesions in Korea (ROCK) registry was a large, retrospective, multicenter study to assess RA treatment of severe coronary artery calcification. MAIN OUTCOME MEASURES: The primary endpoint was target-vessel failure including cardiac death, target-vessel myocardial infarction, and target-vessel revascularization. SAMPLE SIZE: 540 patients followed for a median of 16.1 months. RESULTS: Of the 540 patients, 305 had diabetes (56.5%). The diabetes group had a significantly higher frequency of multivessel disease; comorbidities such as hypertension, dyslipidemia, and chronic kidney disease; and lower ejection fraction of the left ventricle compared to the non-diabetes group (n=235). There were no significant differences in procedure success and complications observed between the two groups. Target vessel failure at 30 days between the diabetes and non-diabetes groups was not statistically significant in a multivariate Cox regression analysis (1.6% vs. 2.6%, adjusted hazard ratio [HR] 0.595, 95% confidence interval [CI] 0.154-2.300, P =.451). During an 18-month follow-up, the risk of target vessel failure was higher (12.5% vs. 8.9%) but the difference was not statistically significant (adjusted HR 1.393, 95% CI 0.782-2.482, P =.260). CONCLUSIONS: Patients with diabetes have a risk of complications comparable to patients without diabetes, and 30-day and 18-month clinical outcomes are similar in severe coronary artery calcification requiring RA, despite having more comorbidities. LIMITATIONS: Retrospective design. Sample size not based on power calculation. CONFLICT OF INTEREST: None. more...
- Published
- 2022
12. Clinical Outcomes of Biodegradable versus Durable Polymer Drug Eluting Stents in Rotational Atherectomy: Results from ROCK Registry
- Author
-
Kyung An Kim, Sung-Ho Her, Kyusup Lee, Ik Jun Choi, Jae-Hwan Lee, Jang Hoon Lee, Sang Rok Lee, Pil Hyung Lee, Seung-Whan Lee, Ki Dong Yoo, Su Nam Lee, Won Young Jang, Donggyu Moon, Keon-Woong Moon, Kyeong Ho Yun, and Hyun-Jong Lee more...
- Subjects
calcified coronary lesion ,rotational atherectomy ,second generation drug eluting stent ,biodegradable polymer ,durable polymer ,General Medicine - Abstract
Background: The aim of this study was to compare the clinical outcomes of biodegradable polymer (BP) versus durable polymer (DP) drug eluting stents (DES) in patients with calcified coronary lesions who underwent rotational atherectomy (RA) and percutaneous coronary intervention (PCI). Methods: This study was based on a multicenter registry which enrolled patients with calcified coronary artery disease who received PCI using RA during between January 2010 and October 2019 from 9 tertiary centers in Korea. The primary outcome was 3-year all-cause mortality, and the secondary outcomes were cardiovascular death and target-lesion failure. Results: A total of 540 patients who underwent PCI using RA were enrolled with a follow-up period of median 16.1 months. From this registry, 272 patients with PCI using DP-DES and 238 patients with BP-SGDES were selected for analysis. PCI with BP-DES was associated with decreased all-cause mortality after propensity score matching (HR 0.414, CI 0.174–0.988) and multivariate Cox regression analysis (HR 0.458, HR 0.224–0.940). BP-DES was also associated with decreased cardiovascular mortality, but there was no difference in TLF between the two groups. Conclusions: BP-DES were associated with favorable outcomes compared to DP-DES in patients undergoing PCI using RA for calcified coronary lesions. more...
- Published
- 2022
13. Association of Glycosylated Hemoglobin with Long-Term Adverse Cardiac Events after Percutaneous Coronary Intervention in Non Diabetes and Controlled Diabetes Patients: An Observational Study from the Korean COACT Registry
- Author
-
Ha-Wook Park, Sung-Ho Her, Jin Jung, Hyunji Chun, and Wook-Sung Chung
- Subjects
Space and Planetary Science ,Paleontology ,glycosylated hemoglobin ,percutaneous coronary intervention ,diabetes mellitus ,adverse cardiac event ,General Biochemistry, Genetics and Molecular Biology ,Ecology, Evolution, Behavior and Systematics - Abstract
Glycosylated hemoglobin (HbA1c) is an established marker associated with cardiovascular risk, even if it is below the diagnostic threshold for diabetes mellitus (DM). However, whether or not prediabetic and controlled diabetic levels of HbA1c are associated with increased major adverse cardiovascular events (MACE) after percutaneous coronary intervention (PCI) remains unclear. This observational study included a total of 9128 patients who underwent PCI in the COACT registry from eight centers in Korea. A total of 2517 non-DM patients were divided into three groups (Groups I, II, III) according to their HbA1c levels and compared with 965 controlled DM patients (HbA1c < 7.0%, Group IV). During 22 months of median follow-up, there was no significant differences in MACE (p = 0.294) and cardiac death (p = 0.105) among the four groups. In addition, there were also no significant differences in MACE (p = 0.058) between Group III and Group IV. Although patients were diagnosed as DM, they had a similar prognosis in the same range of newly diagnosed DM patients in HbA1c, if they were treated well. The results of this study suggest that intensive treatment is required to reach the Hba1c target in diabetic patients with PCI in order to have a similar prognosis to patients not previously diagnosed with diabetes. more...
- Published
- 2022
14. Effect of smoking on clinical outcomes in patients receiving rotational atherectomy in calcified coronary lesions: from the ROCK Registry, South Korea
- Author
-
Won Young Jang, Hyun-Jong Lee, Ki-Dong Yoo, Su Nam Lee, Donggyu Moon, Seung-Wan Lee, Kyeong Ho Yun, Ik Jun Choi, Sang Rok Lee, Keon-Woong Moon, Jang Hoon Lee, Kyusup Lee, Sung-Ho Her, and Jae-Hwan Lee more...
- Subjects
Atherectomy, Coronary ,Coronary angiography ,medicine.medical_specialty ,medicine.medical_treatment ,MEDLINE ,Coronary Artery Disease ,Rotational atherectomy ,Coronary Angiography ,Atherectomy ,Percutaneous Coronary Intervention ,Risk Factors ,Internal medicine ,Republic of Korea ,Tobacco Smoking ,medicine ,Humans ,In patient ,Registries ,Vascular Calcification ,Retrospective Studies ,Health consequences ,business.industry ,Smoking ,Percutaneous coronary intervention ,Retrospective cohort study ,General Medicine ,Treatment Outcome ,Medicine ,Original Article ,business - Abstract
BACKGROUND: Tobacco smoking and its harmful health effects also increase economic burdens globally. Surprisingly, despite the detrimental health consequences of smoking, some studies have shown better survival among smokers compared with non-smokers, a phenomenon called “smoker's paradox”. However, the impact of smoking status on clinical outcomes in severe calcified coronary artery disease (CAD) patients has yet to be reported. OBJECTIVES: Investigate the impact of smoking on clinical outcomes in calcified CAD receiving rotational atherectomy (RA). DESIGN: Retrospective review of medical records. SETTING: Multicenter registry in South Korea. PATIENTS AND METHODS: This multicenter registry included consecutive patients with calcified CAD who underwent RA at nine tertiary centers in Korea between January 2010 and October 2019. MAIN OUTCOME MEASURES: Target-vessel failure (TVF) which included the composite of cardiac death, target-vessel myocardial infarction (TVMI), and target-vessel revascularization (TVR). SAMPLE SIZE: 583 lesions in 540 patients followed for a median of 16.1 months. RESULTS: Lesions were divided into two groups: non-smokers (n=472, 81.0%) and smokers (n=111, 19.0%). TVF in the smoker group was significantly more frequent than in non-smoker group (log rank P =.016). The inverse probability of treatment weighting analysis also showed that smoking was significantly associated with a higher incidence of the primary outcome (HR: 1.617; 95% CI: 1.127–2.320; P =.009), cardiac death (HR 1.912; 95% CI: 1.105-3.311; P =.021), myocardial infarction (HR: 3.914; 95% CI: 1.884-8.132; P P =.029), and TVR (HR: 1.661; 95% CI: 1.043-2.643; P =.032). However, any bleeding was significantly observed less in the smokers. CONCLUSION: Smoking is significantly associated with adverse clinical outcomes in CAD patients requiring RA. LIMITATIONS: Retrospective design. CONFLICTS OF INTEREST: None. more...
- Published
- 2021
- Full Text
- View/download PDF
15. Impact of chronic total occlusion lesions on clinical outcomes in patients receiving rotational atherectomy: results from the ROCK registry
- Author
-
Won Young Jang, Ki-Dong Yoo, Jang Hoon Lee, Jae-Hwan Lee, Su Nam Lee, Keon-Woong Moon, Sung-Ho Her, Seung-Whan Lee, Donggyu Moon, Ik Jun Choi, Hyun-Jong Lee, Sang Rok Lee, Kyeong Ho Yun, and Kyusup Lee more...
- Subjects
Atherectomy, Coronary ,medicine.medical_specialty ,medicine.medical_treatment ,Coronary Artery Disease ,030204 cardiovascular system & hematology ,Coronary Angiography ,Revascularization ,Coronary artery disease ,03 medical and health sciences ,Percutaneous Coronary Intervention ,0302 clinical medicine ,Risk Factors ,Humans ,Medicine ,Registries ,030212 general & internal medicine ,Myocardial infarction ,business.industry ,Incidence (epidemiology) ,Percutaneous coronary intervention ,Vascular surgery ,medicine.disease ,Surgery ,Cardiac surgery ,Treatment Outcome ,Coronary Occlusion ,Chronic Disease ,Conventional PCI ,Cardiology and Cardiovascular Medicine ,business - Abstract
The aim of this study was to investigate the impact of chronic total occlusion (CTO) on clinical outcomes in patients with calcified coronary lesions receiving rotational atherectomy (RA). This multi-center registry enrolled consecutive patients with calcified coronary artery disease who underwent RA during percutaneous coronary intervention (PCI) from 9 tertiary centers in Korea between January 2010 and October 2019. The primary outcome was target-vessel failure (TVF) which included the composite of cardiac death, target-vessel myocardial infarction (TVMI), and target-vessel revascularization (TVR). A total of 583 lesions were enrolled in this registry and classified as CTO (n = 42 lesions, 7.2%) and non-CTO (n = 541 lesions, 92.8%). The CTO group consisted of younger patients who were more likely to have a history of previous percutaneous coronary intervention or coronary artery bypass graft surgery. The incidence of the primary outcome was 14.1% and 16.7% for the non-CTO group and CTO group, respectively. The primary outcomes observed in the two groups were not significantly different (log-rank p = 0.736). The 18-month clinical outcomes of the CTO group were comparable to those of the non-CTO group in multivariate analysis. About 7% of patients requiring RA have CTO lesions and these patients experience similar clinical outcomes compared with those having non-CTO lesions. Use of RA for CTO lesions was safe despite higher procedural complexity. more...
- Published
- 2021
- Full Text
- View/download PDF
16. Admission serum potassium levels and prognosis of vasospastic angina
- Author
-
Seung Hwan Han, Won Woo Seo, Sang Ho Jo, Seong-Sik Cho, Sang Hong Baek, Hyun Jin Kim, Min-Ho Lee, Hack Lyoung Kim, Sung Eun Kim, Sung Ho Her, and Kwan Yong Lee
- Subjects
Male ,medicine.medical_specialty ,Acute coronary syndrome ,endocrine system diseases ,Science ,Cardiology ,Coronary Vasospasm ,Hypokalemia ,030204 cardiovascular system & hematology ,urologic and male genital diseases ,Gastroenterology ,Article ,Angina Pectoris ,03 medical and health sciences ,0302 clinical medicine ,Patient Admission ,Interquartile range ,Internal medicine ,medicine ,Humans ,Cumulative incidence ,In patient ,030212 general & internal medicine ,Proportional Hazards Models ,Vasospastic angina ,Multidisciplinary ,Proportional hazards model ,business.industry ,nutritional and metabolic diseases ,Middle Aged ,medicine.disease ,Prognosis ,Treatment Outcome ,Serum potassium ,Multivariate Analysis ,Potassium ,Medicine ,Female ,medicine.symptom ,business ,Interventional cardiology - Abstract
Hypokalemia is a common electrolyte disturbance and is related to poor prognosis in patients with cardiovascular disease. However, the role of hypokalemia in patients with vasospastic angina (VSA) has not yet been studied. The present study enrolled 1454 patients diagnosed with VSA according to ergonovine provocation test results and available admission serum potassium data. The primary outcome was a composite of cardiac death, acute coronary syndrome, and new-onset life-threatening arrhythmia. Based on a hypokalemia definition as serum potassium concentration ≤ 3.5 mEq/L, the hypokalaemia group included 70 patients (4.8%). The median potassium levels were 3.4 mEq/L [interquartile range (IQR) 3.3–3.5] in the hypokalemia group and 4.1 mEq/L (IQR 3.9–4.3) in the no-hypokalemia group. The median follow-up duration was 764 days. Primary outcomes occurred in seven patients (10.0%) in the hypokalemia group and 51 patients (3.7%) in the no-hypokalemia group. The Kaplan–Meier analysis showed a higher cumulative incidence of primary outcomes in the hypokalemia group compared to that in the no-hypokalemia group (log-rank P = 0.014). Multivariate Cox regression analysis also showed that hypokalemia was an independent predictor of primary outcomes. In conclusion, hypokalemia at admission was associated with adverse clinical outcomes in VSA. more...
- Published
- 2021
17. Impact of Diabetes Duration on Clinical Outcome in Patients Receiving Rotational Atherectomy in Calcified Lesions in Korea-Results from ROCK Registry
- Author
-
Jin Jung, Sung-Ho Her, Kyusup Lee, Ji-Hoon Jung, Ki-Dong Yoo, Keon-Woong Moon, Donggyu Moon, Su-Nam Lee, Won-Young Jang, Ik-Jun Choi, Jae-Hwan Lee, Jang-Hoon Lee, Sang-Rok Lee, Seung-Whan Lee, Kyeong-Ho Yun, and Hyun-Jong Lee more...
- Subjects
Space and Planetary Science ,Paleontology ,coronary artery calcification ,diabetic duration ,rotational atherectomy ,clinical outcome ,General Biochemistry, Genetics and Molecular Biology ,Ecology, Evolution, Behavior and Systematics - Abstract
There are limited data regarding the clinical impact of diabetes duration for patients with heavy calcified coronary lesions. We sought to determine the clinical impact of diabetes duration on clinical outcomes in patients with heavily calcified lesions who required rotational atherectomy during percutaneous coronary intervention (PCI). A total of 540 diabetic patients (583 lesions) were enrolled between January 2010 and October 2019. Patients were classified into three subgroups: patients with no diabetes mellitus (non-DM), shorter duration (S-DM), and longer duration (L-DM), of which duration was divided at 10 years. During 18 months of follow-up-duration, diabetes duration was significantly associated with the primary outcome. The incidence rate of target-vessel failure (TVF), the primary outcome, was significantly higher in the L-DM group compared with non-DM or S-DM. Among secondary outcomes, any repeat revascularization (RR) was frequently observed in the L-DM compared with other groups. In multivariate analysis, the risk of TVF and any RR was 1.9 times and 2.4 times higher in L-DM than in non-DM, respectively. This study firstly demonstrated that there is an association between a longer DM duration and poor clinical outcomes in patients with severe calcified CAD after PCI. More careful monitoring for recurrence is needed during follow-up in those patients. more...
- Published
- 2022
18. Safety and Efficacy of Pitavastatin in Patients With Impaired Fasting Glucose and Hyperlipidemia: A Randomized, Open-labeled, Multicentered, Phase IV Study
- Author
-
Hae Young Lee, Hyeon Cheol Gwon, Dong-Ju Choi, Pum Joon Kim, Woo Baek Chung, Seung-Woon Rha, Kyoo Rok Han, Si Wan Choi, Woo Shik Kim, Ki Hoon Han, Bum-Kee Hong, Kyung Tae Jung, Jei Keon Chae, Tae Ho Park, Eun-Seok Shin, Sung Ho Her, Myung Ho Jeong, So-Yeon Choi, Jong Min Lee, Jong Seon Park, and Namsik Chung more...
- Subjects
Blood Glucose ,Male ,medicine.medical_specialty ,Apolipoprotein B ,medicine.medical_treatment ,Hypercholesterolemia ,Hyperlipidemias ,02 engineering and technology ,030204 cardiovascular system & hematology ,Gastroenterology ,03 medical and health sciences ,020210 optoelectronics & photonics ,0302 clinical medicine ,Internal medicine ,Diabetes mellitus ,Hyperlipidemia ,0202 electrical engineering, electronic engineering, information engineering ,medicine ,Humans ,Pharmacology (medical) ,Pitavastatin ,Aged ,Apolipoproteins B ,Glycated Hemoglobin ,Pharmacology ,Apolipoprotein A-I ,biology ,Adiponectin ,business.industry ,Insulin ,Fasting ,Middle Aged ,medicine.disease ,Impaired fasting glucose ,Lipids ,Cholesterol ,Quinolines ,biology.protein ,Female ,Apolipoprotein A1 ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,business ,medicine.drug - Abstract
Purpose Although the role of high-intensity lipid-lowering therapy in cardiovascular protection has broadened, concerns still exist about new-onset diabetes mellitus (NODM), especially in vulnerable patients. This study aimed to compare the effect of high-dose (4 mg/d) and usual dose (2 mg/d) pitavastatin on glucose metabolism in patients with hyperlipidemia and impaired fasting glucose (IFG). Methods In this 12-month study, glucose tolerance and lipid-lowering efficacy of high-dose pitavastatin (4 mg [study group]) was compared with that of usual dose pitavastatin (2 mg [control group]) in patients with hyperlipidemia and IFG. The primary end point was the change of glycosylated hemoglobin (HbA1c) after 24 weeks of treatment. The secondary end points were as follows: (1) NODM within 1 year after treatment, (2) change of lipid parameters, (3) changes of adiponectin, and (4) change of blood glucose and insulin levels. Findings Of the total 417 patients screened, 313 patients with hypercholesterolemia and IFG were randomly assigned into groups. The mean (SD) change in HbA1c was 0.06% (0.20%) in the study group and 0.03% (0.22%) in the control group (P = 0.27). Within 1 year, 27 patients (12.3%) developed NODM, including 12 (10.6%) of 113 patients in the study group and 15 (14.2%) of 106 in the control group (P = 0.43). The study group had a significantly higher reduction of total cholesterol and LDL-C levels and a higher increase in apolipoprotein A1/apolipoprotein B ratio (0.68 [0.40] vs 0.51 [0.35], P Implications The high-dose pitavastatin therapy did not aggravate glucose metabolism compared with the usual dose therapy. Moreover, it had a better effect on cholesterol-lowering and apolipoprotein distribution in the patients with hyperlipidemia and IFG. more...
- Published
- 2020
- Full Text
- View/download PDF
19. Comparative effectiveness analysis of percutaneous coronary intervention versus coronary artery bypass grafting in patients with chronic kidney disease and unprotected left main coronary artery disease
- Author
-
Pil Hyung Lee, Cheol Whan Lee, Ha Wook Park, Dae-Won Kim, Seung-Jung Park, Do-Yoon Kang, Mahn-Won Park, Sang Yong Om, Seong-Wook Park, Jung-Min Ahn, Sung-Ho Her, and Duk-Woo Park
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Renal function ,Coronary Artery Disease ,030204 cardiovascular system & hematology ,Revascularization ,03 medical and health sciences ,Percutaneous Coronary Intervention ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,cardiovascular diseases ,030212 general & internal medicine ,Myocardial infarction ,Coronary Artery Bypass ,Renal Insufficiency, Chronic ,Stroke ,business.industry ,Hazard ratio ,Percutaneous coronary intervention ,medicine.disease ,Treatment Outcome ,Conventional PCI ,Cardiology ,Cardiology and Cardiovascular Medicine ,business ,Kidney disease - Abstract
AIMS Outcomes according to the status of renal insufficiency have not been fully evaluated in left main coronary artery disease (LMCAD). In the present study therefore, we sought to evaluate clinical outcomes in patients with significant LMCAD stratified by the degree of renal insufficiency and the relative clinical outcomes after PCI and CABG stratified by the differential levels of renal function using data from the large multinational "all-comers" Interventional Research Incorporation Society-Left MAIN Revascularization (IRIS-MAIN) registry. METHODS AND RESULTS Among 4,894 patients with LMCAD, renal insufficiency was graded according to the estimated glomerular filtration rate (eGFR). The primary outcome was major adverse cardiac and cerebrovascular events (MACCE), defined as death, myocardial infarction, stroke, or any revascularisation. The patients were stratified into three groups according to eGFR: 3,824 (78%) in group 1 (eGFR ≥60 ml·min-1·1.73 m2), 838 (17%) in group 2 (eGFR ≥30 and more...
- Published
- 2020
- Full Text
- View/download PDF
20. Comparison between angiotensin-converting enzyme inhibitor and angiotensin receptor blocker after percutaneous coronary intervention
- Author
-
Yong-Giun Kim, Sung Ho Her, Dae-Won Kim, Mahn-Won Park, Shin-Jae Kim, Gyung-Min Park, Sang-Gon Lee, Soe Hee Ann, Martin H. Strauss, Yujin Yang, Young-Rak Cho, Ki-Bum Won, Seung-Whan Lee, and Seungbong Han more...
- Subjects
medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Angiotensin-Converting Enzyme Inhibitors ,030204 cardiovascular system & hematology ,Cohort Studies ,Angina ,Coronary artery disease ,Angiotensin Receptor Antagonists ,03 medical and health sciences ,Percutaneous Coronary Intervention ,0302 clinical medicine ,Interquartile range ,Internal medicine ,Republic of Korea ,medicine ,Clinical endpoint ,Humans ,Registries ,cardiovascular diseases ,030212 general & internal medicine ,Myocardial infarction ,business.industry ,Hazard ratio ,Percutaneous coronary intervention ,medicine.disease ,Conventional PCI ,Cardiology and Cardiovascular Medicine ,business - Abstract
Background The inhibitors for renin-angiotensin-aldosterone system (RAAS) have different mechanisms of action in coronary artery disease (CAD). This study sought to compare the clinical outcomes between angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) therapy in patients with CAD undergoing contemporary percutaneous coronary intervention (PCI). Methods Based on the National Health Insurance claims data in South Korea, patients aged 18 years or older who had undergone PCI between July 2011 and June 2015 were enrolled. The study participants were classified either as patients with acute myocardial infarction (AMI, n = 21,747) or angina (n = 28,708). And according to the post PCI discharge medications, patients were categorized into ACEI and ARB therapy groups. The primary endpoint was all-cause death, and the two groups were compared using a propensity-score matching analysis. Results The study population had a median follow-up of 2.2 years (interquartile range, 1.2–3.2). In the propensity-score matched AMI group (8341 pairs), the occurrence of all-cause death was significantly lower in the ACEI group than in the ARB group (hazard ratio [HR] of ACEI, 0.823; 95% confidence interval [CI]: 0.715–0.947; p = 0.006). In the propensity-score matched angina group (10,878 pairs), there was no difference in the incidence of the primary endpoint between the ACEI and ARB groups (HR of ACEI, 1.113; 95% CI: 0.986–1.257; p = 0.084). Conclusions In this nationwide Korean cohort study, ACEI therapy in patients with AMI and concomitant PCI showed a significant reduction in all-cause mortality rates when compared to that with ARB therapy. more...
- Published
- 2020
- Full Text
- View/download PDF
21. Additional postdilatation using noncompliant balloons after everolimus‐eluting stent implantation: Results of the PRESS trial
- Author
-
Kyung Tae Jung, In Whan Seong, Jon Suh, Jin Ok Jeong, Woong Gil Choi, Si Wan Choi, Gyung Min Park, Se Whan Lee, Eun-Seok Shin, Jaebeom Lee, Ju Yeol Baek, Hyuck Jun Yoon, Sung Ho Her, In Ho Chae, Jae-Hwan Lee, Jin Bae Lee, So-Yeon Choi, Jang Whan Bae, and Rak Kyeong Choi more...
- Subjects
Male ,medicine.medical_specialty ,Randomization ,Everolimus eluting stent ,medicine.medical_treatment ,Clinical Investigations ,Coronary Artery Disease ,030204 cardiovascular system & hematology ,Coronary Angiography ,Prosthesis Design ,Coronary Restenosis ,Coronary artery disease ,03 medical and health sciences ,0302 clinical medicine ,drug‐eluting stent ,Clinical endpoint ,medicine ,Humans ,Everolimus ,Prospective Studies ,030212 general & internal medicine ,Myocardial infarction ,Angioplasty, Balloon, Coronary ,business.industry ,Stent ,Drug-Eluting Stents ,General Medicine ,Middle Aged ,medicine.disease ,noncompliant balloon ,Surgery ,postdilatation ,Treatment Outcome ,Drug-eluting stent ,High pressure ,everolimus‐eluting stent ,Female ,Cardiology and Cardiovascular Medicine ,business ,Immunosuppressive Agents ,Follow-Up Studies - Abstract
Background There are limited data on the clinical value of routine postdilatation using noncompliant balloons after contemporary drug‐eluting stent implantation. Hypothesis Additional postdilatation using noncompliant balloons after everolimus‐eluting stent implantation could provide better clinical outcomes. Methods We randomly assigned 1774 patients with coronary artery disease to undergo additional high‐pressure postdilatation using noncompliant balloons and moderate‐pressure dilatation using stent balloons after everolimus‐eluting stent implantation. The primary endpoint was a composite of death, myocardial infarction (MI), stent thrombosis, and target vessel revascularization (TVR) 2 years after randomization. Results The study was discontinued early owing to slow enrollment. In total, 810 patients (406 patients in the high pressure group and 404 in the moderate pressure group) were finally enrolled. At 2 years, the primary endpoint occurred in 3.6% of patients in the high pressure group and in 4.4% of those in the moderate pressure group (P = .537). In addition, no significant differences were observed between the two groups in the occurrence of an individual end point of death (0.8% in the high pressure group vs 1.5% in the moderate group, P = .304), MI (0.2% vs 0.5%, P = .554), stent thrombosis (0% vs 0.2%, P = .316), or TVR (2.8% vs 2.6%, P = .880). Conclusions The strategy of routine postdilatation using noncompliant balloons after everolimus‐eluting stent implantation did not provide incremental clinical benefits. more...
- Published
- 2020
- Full Text
- View/download PDF
22. Nitrates vs. Other Types of Vasodilators and Clinical Outcomes in Patients with Vasospastic Angina: A Propensity Score-Matched Analysis
- Author
-
Hyun-Jin Kim, Sang-Ho Jo, Min-Ho Lee, Won-Woo Seo, Hack-Lyoung Kim, Kwan Yong Lee, Tae-Hyun Yang, Sung-Ho Her, Byoung-Kwon Lee, Keun-Ho Park, Youngkeun Ahn, Seung-Woon Rha, Hyeon-Cheol Gwon, Dong-Ju Choi, and Sang Hong Baek more...
- Subjects
vasospastic angina ,nitrate ,vasodilator ,acute coronary syndrome ,General Medicine - Abstract
Although vasodilators are widely used in patients with vasospastic angina (VA), few studies have compared the long-term prognostic effects of different types of vasodilators. We investigated the long-term effects of vasodilators on clinical outcomes in VA patients according to the type of vasodilator used. Study data were obtained from a prospective multicenter registry that included patients who had symptoms suggestive of VA. Patients were classified into two groups according to use of nitrates (n = 239) or other vasodilators (n = 809) at discharge. The composite clinical events rate, including acute coronary syndrome (ACS), cardiac death, new-onset arrhythmia (including ventricular tachycardia and ventricular fibrillation), and atrioventricular block, was significantly higher in the nitrates group (5.3% vs. 2.2%, p = 0.026) during one year of follow-up. Specifically, the prevalence of ACS was significantly more frequent in the nitrates group (4.3% vs. 1.5%, p = 0.024). After propensity score matching, the adverse effects of nitrates remained. In addition, the use of nitrates at discharge was independently associated with a 2.69-fold increased risk of ACS in VA patients. In conclusion, using nitrates as a vasodilator at discharge can increase the adverse clinical outcomes in VA patients at one year of follow-up. Clinicians need to be aware of the prognostic value and consider prescribing other vasodilators. more...
- Published
- 2022
23. Prognostic Impact of Chronic Vasodilator Therapy in Patients With Vasospastic Angina
- Author
-
Yongwhan Lim, Min Chul Kim, Youngkeun Ahn, Kyung Hoon Cho, Doo Sun Sim, Young Joon Hong, Ju Han Kim, Myung Ho Jeong, Sang Hong Baek, Sung‐Ho Her, Kwan Yong Lee, Seung Hwan Han, Seung‐Woon Rha, Dong‐Ju Choi, Hyeon‐Cheol Gwon, Hyuck Moon Kwon, Tae‐Hyun Yang, Keun‐Ho Park, and Sang‐Ho Jo more...
- Subjects
Angina Pectoris, Variant ,Vasodilator Agents ,Coronary Vasospasm ,Humans ,Prospective Studies ,Cardiology and Cardiovascular Medicine ,Coronary Angiography ,Prognosis - Abstract
Background Chronic vasodilator therapy with long‐acting nitrate is frequently used to treat vasospastic angina. However, the clinical benefits of this approach are controversial. We investigated the prognostic impact of vasodilator therapy in patients with vasospastic angina from the multicenter, prospective VA‐KOREA (Vasospastic Angina in KOREA) registry. Methods and Results We analyzed data from 1895 patients with positive intracoronary ergonovine provocation test results. The patients were divided into 4 groups: no vasodilator (n=359), nonnitrate vasodilator (n=1187), conventional nitrate (n=209), and a combination of conventional nitrate and other vasodilators (n=140). The primary end point was a composite of cardiac death, acute coronary syndrome, and new‐onset arrhythmia at 2 years. Secondary end points were the individual components of the primary end point, all‐cause death, and rehospitalization due to recurrent angina. The groups did not differ in terms of the risk of the primary end point. However, the acute coronary syndrome risk was significantly higher in the conventional nitrate (hazard ratio [HR], 2.49; 95% CI, 1.01–6.14; P =0.047) and combination groups (HR, 3.34; 95% CI, 1.15–9.75, P =0.027) compared with the no‐vasodilator group, as assessed using the inverse probability of treatment weights. Subgroup analyses revealed prominent adverse effects of nitrate in patients with an intermediate positive ergonovine provocation test result and in those with low Japanese Coronary Spasm Association scores. Conclusions Long‐acting nitrate‐based chronic vasodilator therapy was associated with an increased 2‐year risk of acute coronary syndrome in patients with vasospastic angina, especially in low‐risk patients. more...
- Published
- 2022
24. Impact of Diabetes duration on Clinical outcome in Patients receiving Rotational Atherectomy from ROCK Registry : a multicenter, retrospective study
- Author
-
JIN JUNG, Sung-Ho Her, Kyusup Lee, Ji-Hoon Jung, Ki-Dong You, Keon-Woong Moon, Donggyu Moon, Su Nam Lee, Won Young Jang, Ik Jun Choi, Jae Hwan Lee, Jang Hoon Lee, Sang Rok Lee, Seung-Whan Lee, Kyeong Ho Yun, and Hyun-Jong Lee more...
- Abstract
Background: There are limited data regarding the clinical impact of diabetes duration for patients with heavy calcified coronary lesions. We sought to determine the clinical impact of diabetes duration on clinical outcomes in patients with heavily calcified lesions required rotational atherectomy (RA) during percutaneous coronary intervention (PCI).Methods: A total of 540 diabetic patients (583 lesions) were enrolled between January 2010 and October 2019. Patients were classified into 3 subgroups: patients with no diabetes mellitus (non-DM), shorter duration of DM (S-DM), and longer duration of DM (L-DM), of which duration was divided at 10 years. The primary outcome was target-vessel failure (TVF), a composite outcome of cardiac death, target-vessel myocardial infarction, or target-vessel revascularization.Results: During 18 months of follow-up-duration, diabetes duration was significantly associated with the primary outcome. The incidence rate of TVF, primary outcome, was significantly higher in the L-DM group compared with non-DM or S-DM groups (non-DM, 30 [12.0%] vs. S-DM, 9 [13.9%] vs. L-DM, 29 [21.6%]; p=0.039). Among secondary outcomes, any repeat revascularization was frequently observed in the L-DM compared with other groups (non-DM, 19 [7.6%] vs. S-DM, 6 [9.2%] vs. L-DM, 21 [15.7%]; p=0.042). In multivariate analysis, the risk of TVF and any RR was 1.9 times and 2.4 times higher in L-DM than in non-DM, respectively. Conclusions: This study was firstly demonstrated that the association between a longer DM duration and poor clinical outcomes in patients with severe calcified CAD after PCI. More careful monitoring for recurrence is needed during follow-up in those patients more...
- Published
- 2022
- Full Text
- View/download PDF
25. Association between lung function and the risk of atrial fibrillation in a nationwide population cohort study
- Author
-
Su Nam, Lee, Seung-Hyun, Ko, Sung-Ho, Her, Kyungdo, Han, Donggyu, Moon, Sung Kyoung, Kim, Ki-Dong, Yoo, and Yu-Bae, Ahn
- Subjects
Adult ,Cohort Studies ,Multidisciplinary ,Risk Factors ,Forced Expiratory Volume ,Atrial Fibrillation ,Vital Capacity ,Humans ,respiratory system ,Lung ,respiratory tract diseases - Abstract
We investigated the association between lung function and atrial fibrillation (AF) in 21,349 adults without AF aged ≥ 40 years who underwent spirometry. The study participants were enrolled from the Korean National Health and Nutritional Examination Survey between 2008 and 2016. The primary outcome was new-onset non-valvular AF identified from the National Health Insurance Service database. During the median follow-up of 6.5 years, 2.15% of participants developed new-onset AF. The incidence rate of AF per 1000 person-years was inversely related to the forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), and FEV1/FVC quartile. After adjustment for multiple variables, the AF risk in the lowest FEV1 quartile was 1.64-fold higher than that in the highest quartile (hazard ratio (HR) 1.64 (95% confidence interval (CI) 1.26–2.12) for lowest FEV1 quartile). The lowest quartile of FVC had 1.56-fold higher AF risk than the highest quartile (HR 1.56 (95% CI 1.18–2.08) for lowest FVC quartile). Although the lowest FEV1/FVC quartile was associated with an increased risk of AF in the unadjusted model, this increased risk was not statistically significant in the multivariable analysis. Compared to those with normal lung function, participants with restrictive or obstructive lung function had 1.49 and 1.42-fold higher AF risks, respectively. In this large nationwide cohort study, both obstructive and restrictive patterns of reduced lung function were significantly associated with increased AF risk. more...
- Published
- 2022
- Full Text
- View/download PDF
26. E-9 | Intravascular Ultrasound Guided Percutaneous Coronary Intervention for Complex Calcified Lesion Requiring Rotational Atherectomy
- Author
-
Hyun-Jong Lee, Duck Hyun Jang, Kyusup Lee, Sung-Ho Her, Ik-Jun Choi, Jae-Hwan Lee, Sang-Rok Lee, Seung W. Lee, Jang-Hoon Lee, Pil-Hyung Lee, and Kyeong-Ho Yun
- Published
- 2023
- Full Text
- View/download PDF
27. Impact of Diabetes Duration on Clinical Outcome in Patients Receiving Rotational Atherectomy from ROCK Registry
- Author
-
Jin Jung, Sung-Ho Her, Kyusup Lee, Ki-Dong Yoo, Keon-Woong Moon, Donggyu Moon, Su Nam Lee, Won Young Jang, Ik Jun Choi, Jae Hwan Lee, Jang Hoon Lee, Sang Rok Lee, Seung-Whan Lee, Kyeong Ho Yun, and Hyun-Jong Lee more...
- Published
- 2022
- Full Text
- View/download PDF
28. Prognostic Impact of Periprocedural Myocardial Infarction in Patients with Heavily Calcified Coronary Artery Disease Receiving Rotational Atherectomy
- Author
-
Hyun-Jong Lee, Kyeong Ho Yun, Seung-Whan Lee, Sang Rok Lee, Jang Hoon Lee, Jae-Hwan Lee, Ik Jun Choi, Won Young Jang, Su Nam Lee, Donggyu Moon, Keon-Woong Moon, Ki-Dong Yoo, Kyusup Lee, Sung-Ho Her, and Jin Jung more...
- Subjects
General Medicine ,Cardiology and Cardiovascular Medicine - Published
- 2023
- Full Text
- View/download PDF
29. Gender Differences in the Impact of New-Onset Atrial Fibrillation on Long-Term Risk of Ischemic Stroke after Acute Myocardial Infarction
- Author
-
Eun-Ho Choo, Doo-Soo Jeon, Byung-Hee Hwang, Sung-Ho Her, Jongmin Lee, Jeong-Eun Yi, Ik Jun Choi, Dong-Bin Kim, Mahn-Won Park, Myung Ho Jeong, Pum-Joon Kim, Kiyuk Chang, Sungmin Lim, Kwan-Yong Lee, Chul Soo Park, Wook-Sung Chung, Youngkeun Ahn, Ki-Dong Yoo, Suk-Min Seo, Chan-Joon Kim, and Hee-Yeol Kim more...
- Subjects
Acute coronary syndrome ,medicine.medical_specialty ,business.industry ,Hazard ratio ,acute myocardial infarction ,Atrial fibrillation ,General Medicine ,medicine.disease ,Article ,Confidence interval ,gender differences ,Interquartile range ,Internal medicine ,new onset atrial fibrillation ,ischemic stroke ,medicine ,Cardiology ,Medicine ,Myocardial infarction ,Risk factor ,business ,Stroke - Abstract
Background: Atrial fibrillation (AF) has been identified as a major risk factor for mortality after acute coronary syndrome (ACS). However, the long-term risk of ischemic stroke associated with new-onset atrial fibrillation (NOAF) in ACS remains controversial, and its gender-specific association is unknown. Methods: We analyzed the data of 10,137 ACS survivors included in a multicenter, prospective registry for Korean patients with acute myocardial infarction (AMI) between January 2004 and August 2014. Subjects were categorized into three groups (non-AF vs. NOAF vs. previous AF) based on medical history and electrocardiographic evidence of AF, either at admission or during hospitalization. Results: Among the total study population (72.3% men), 370 patients (3.6%) had NOAF and 130 (1.3%) had previous AF. During a median follow-up of 61 months (interquartile range, 38.8 to 89.3 months), 245 (2.4%) patients (218 (2.3%) non-AF vs. 15 (4.1%) NOAF vs. 12 (9.2%) previous AF, p <, 0.001) experienced ischemic stroke. After adjustment for confounding variables, both NOAF (adjusted hazard ratio (HR) 1.87, 95% confidence interval (CI) 1.09–3.24, p = 0.024) and previous AF (adjusted HR 4.00, 95% CI 2.03–7.87, p <, 0.001), along with older age, diabetes, current smoker, and previous stroke were independent risk factors of ischemic stroke. In the gender-stratified analysis, men with previous AF but not NOAF had a significantly higher risk of ischemic stroke (adjusted HR 4.14, 95% CI 1.79–9.55, p = 0.001) than those without AF. In women, NOAF (adjusted HR 2.54, 95% CI 1.21–5.35, p = 0.014) as well as previous AF (adjusted HR 3.72, 95% CI 1.16–11.96, p = 0.028) was a strong predictor of ischemic stroke, and the predictive value was comparable to that of previous AF among patients with a CHA2DS2-VASc score ≥ 2. Conclusions: Both NOAF and previous AF were associated with ischemic stroke after AMI, but the impact of NOAF as a risk factor of ischemic stroke was significant only in women. more...
- Published
- 2021
30. Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration, Multicenter, Phase IV Study (Fimasartan Achieving Systolic Blood Pressure Target (FAST) Study)
- Author
-
Woo-Baek Chung, Sung-Ho Her, Ki-Dong Yoo, Kiyuk Chang, Sung-Won Jang, Jongmin Lee, Chul Soo Park, Ki-Bae Seung, Doo-Soo Jeon, and Sang-Hyun Ihm
- Subjects
0301 basic medicine ,Adult ,Male ,medicine.medical_specialty ,Ambulatory blood pressure ,Pharmaceutical Science ,Tetrazoles ,Blood Pressure ,Essential hypertension ,Double blind ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,24 hr ambulatory blood pressure monitoring ,Double-Blind Method ,Internal medicine ,Drug Discovery ,Republic of Korea ,medicine ,Humans ,Fimasartan ,antihypertensive ,angiotensin receptor blocker ,Antihypertensive Agents ,Original Research ,Aged ,Pharmacology ,Drug Design, Development and Therapy ,Dose-Response Relationship, Drug ,business.industry ,Biphenyl Compounds ,essential hypertension ,Imidazoles ,Blood Pressure Monitoring, Ambulatory ,Middle Aged ,medicine.disease ,030104 developmental biology ,Blood pressure ,Pyrimidines ,Valsartan ,030220 oncology & carcinogenesis ,Ambulatory ,Cardiology ,Female ,Olmesartan ,business ,medicine.drug - Abstract
Woo-Baek Chung,1 Sang-Hyun Ihm,2 Sung-Won Jang,3 Sung-Ho Her,4 Chul Soo Park,5 Jong-Min Lee,6 Kiyuk Chang,1 Doo-Soo Jeon,7 Ki-Dong Yoo,8 Ki-Bae Seung1 1Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 2Division of Cardiology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 3Division of Cardiology, Department of Internal Medicine, St. Paul’s Hospital; 4Daejeon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 5Division of Cardiology, Department of Internal Medicine, Yeouido St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 6Division of Cardiology, Department of Internal Medicine, Uijeongbu St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 7Division of Cardiology, Department of Internal Medicine, In-Cheon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 8Division of Cardiology, Department of Internal Medicine, St. Vincent’s Hospital, The Catholic University of Korea, Seoul, Republic of KoreaCorrespondence: Sang-Hyun IhmDivision of Cardiology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 14647, 327, Sosa-ro, Bucheon-si, Gyeonggi-do, Republic of KoreaTel +82-32-340-7027Fax +82-32-340-2669Email heartihmsh@yahoo.co.krKi-Bae SeungDivision of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 06591, 222, Banpo-daero, Seocho-gu, Seoul, Republic of KoreaTel +82-2-2258-1134Fax +82-2-591-1506Email kbseung@catholic.ac.krPurpose: Head-to-head comparison of the blood pressure (BP) lowering effect of fimasartan versus valsartan, with olmesartan as a reference, on office blood pressure and ambulatory BP.Patients and Methods: Of the 369 randomly assigned patients in this study, 365 hypertensive patients were referred as the full analysis set and divided into 3 groups with a 3:3:1 ratio (fimasartan group: 155, valsartan group: 157, olmesartan group: 53). After the 2-week single-blind placebo run-in period, initial standard doses of 60-mg fimasartan, 80-mg valsartan, and 10-mg olmesartan were administered for 2 weeks, then forcibly up-titrated higher doses (fimasartan 120 mg, valsartan 160 mg, olmesartan 20 mg) were given for 4 weeks. ABP was measured before and after the 6-week treatment. Primary endpoint was reduction of sitting office systolic BP (SiSBP) of fimasartan compared to valsartan after 6 weeks. Secondary endpoints were reduction of sitting office diastolic BP (SiDBP) and 24 hrs, day-time, and night-time mean systolic and diastolic ABP (ASBP, ADBP) after 6 weeks.Results: Patients’ mean age was 58.34± 7.68 years, and 289 patients were male (79.18%). After the 6-week treatment, SiSBP reduction of fimasartan and valsartan were − 16.26± 15.07 and − 12.81± 13.87 (p=0.0298) and SiDBP were − 7.63± 9.67 and − 5.14± 8.52 (p=0.0211). Reductions in 24 hrs mean ASBP were − 15.22± 13.33 and − 9.45± 12.37 (p=0.0009), and ADBPs were − 8.74± 7.55 and − 5.98± 7.85 (p=0.0140). Reductions of night-time ASBPs were − 16.80± 15.81 and − 10.32± 14.88 (p=0.0012), and those of night-time ADBPs were − 8.89± 9.93 and − 5.55± 9.70 (p=0.0152). Reduction of BP in olmesartan group did not demonstrate significant difference with fimasartan group in all end-points.Conclusion: Fimasartan 120-mg treatment demonstrated superior efficacy in reduction of SiSBP, SiDBP, and 24 hrs ASBP and ADBP compared to valsartan 160 mg. Reduction of night-time ASBP from baseline was largest in fimasartan group, suggesting that fimasartan may be effective for recovering dipping pattern.NCT number: NCT02495324 (Fimasartan Achieving SBP Target (FAST) study).Keywords: 24 hr ambulatory blood pressure monitoring, angiotensin receptor blocker, essential hypertension, antihypertensive more...
- Published
- 2020
31. A Retrospective Study of LDL-Cholesterol in Koreans on Atorvastatin/Ezetimibe or Atorvastatin Monotherapy
- Author
-
Kiyuk Chang, Doo-Soo Jeon, Chang Hwan Yoon, Jung Sun Kim, Byung-Hee Hwang, Sung-Ho Her, Hyun Won Shin, Chang-Wook Nam, Jin Won Kim, Jong-Min Lee, Sung Uk Kwon, Sang Hyun Ihm, and Jang-Whan Bae
- Subjects
Ldl cholesterol ,medicine.medical_specialty ,business.industry ,Atorvastatin ,Urology ,medicine ,Retrospective cohort study ,ATORVASTATIN/EZETIMIBE ,business ,medicine.drug - Published
- 2019
- Full Text
- View/download PDF
32. Clopidogrel plus Aspirin Use is Associated with Worse Long-Term Outcomes, but Aspirin Use Alone is Safe in Patients with Vasospastic Angina: Results from the VA-Korea Registry, A Prospective Multi-Center Cohort
- Author
-
Sang Hong Baek, Sung Ho Her, Min Ho Lee, Hyeon Cheol Gwon, Kwan Yong Lee, Tae Hyun Yang, Sang Ho Jo, Sung Eun Kim, Seung-Woon Rha, Keun Ho Park, Byoung Kwon Lee, Jung-Won Suh, Seung Hwan Han, Won Woo Seo, and Seong-Sik Cho more...
- Subjects
Angina Pectoris, Variant ,Male ,medicine.medical_specialty ,Acute coronary syndrome ,lcsh:Medicine ,030204 cardiovascular system & hematology ,Chest pain ,Article ,Coronary artery disease ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Republic of Korea ,medicine ,Humans ,Prospective Studies ,Prospective cohort study ,lcsh:Science ,Aged ,Aspirin ,Multidisciplinary ,business.industry ,Hazard ratio ,lcsh:R ,Middle Aged ,Translational research ,Clopidogrel ,medicine.disease ,Comorbidity ,Treatment Outcome ,Drug Therapy, Combination ,Female ,lcsh:Q ,medicine.symptom ,business ,Interventional cardiology ,Platelet Aggregation Inhibitors ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Anti-platelet agents are commonly used in vasospastic angina (VA) patients with comorbidity like coronary artery disease. However, long-term clinical outcomes in the use of aspirin, clopidogrel or the two agents together have rarely been investigated in VA patients. In a prospective study, we enrolled 2960 patients who received coronary angiography and ergonovine provocation test at 11 university hospitals in Korea. Among them, 1838 patients were diagnosed either with definite (n = 680) or intermediate (n = 1212) VA, using the criteria of chest pain, ECG changes and ergonovine provocation test results. They were analyzed according to their use of aspirin, clopidogrel or both, or no anti-platelet agent at all. The primary outcome was time to composite events of death from any cause, acute coronary syndrome (ACS) and symptomatic arrhythmia during a 3-year follow-up. A primary composite outcome was significantly more common in the aspirin plus clopidogrel group, at 10.8% (14/130), as compared with the non-antiplatelet group, at 4.4% (44/1011), (hazard ratio [HR] 2.41, 95% confidence interval [CI], 1.32–4.40, p = 0.004). With regard to the person-time event rate, similar results were shown, with the highest rate in the aspirin plus clopidogrel user at 4.72/1000 person months (95% CI, 2.79–7.96, log-rank test for primary outcome p = 0.016). The person-time event of the ACS rate was also highest in that group, at 2.81 (95% CI, 1.46–5.40, log-rank test for ACS p = 0.116). Kaplan-Meier survival analysis demonstrated poor prognosis in primary outcomes and ACS in aspirin plus clopidogrel users (log-rank test, p = 0.005 and p = 0.0392, respectively). Cox-proportional hazard regression analysis, adjusting for age, sex, history of coronary heart disease, hypertension, diabetes, presence or not of definite spasm, use of calcium channel blocker, demonstrated that the use of aspirin plus clopidogrel is an independent risk for the primary outcome (HR 2.01, CI: 1.07–3.81, p = 0.031). The aspirin-alone group had a similar primary and individual event rate compared to the no-antiplatelet agent group (HR 0.96, CI, 0.59–1.55, p = 0.872). Smokers using aspirin plus clopidogrel had poorer outcomes than non-smokers, with HR 6.36 (CI 2.31–17.54, p = 0.045 for interaction). In conclusion, among VA patients, aspirin plus clopidogrel use is associated with a poor clinical outcome at 3 years, especially in ACS. Aspirin alone appears to be safe for use in those patients. more...
- Published
- 2019
- Full Text
- View/download PDF
33. Efficacy and Safety of Omega-3 Fatty Acids in Patients Treated with Statins for Residual Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
- Author
-
In Kyung Jeong, Dong-Bin Kim, Mi-Seung Shin, Sang Ah Lee, Seung Ho Kang, Kyung Mook Choi, Moon Kyu Lee, Yong Ho Lee, Sung Hee Choi, Ji Eun Jun, Jae Hyuk Lee, Seok Yeon Kim, Jin Man Cho, Jae Myung Yu, Sung Rae Kim, Ho-Cheol Kang, Hyeong Kyu Park, Kyung Ah Han, Won-Yong Shin, Hyuk-Sang Kwon, Sung Ho Her, Ji Oh Mok, In Kye Lee, Kyung Heon Won, So Hun Kim, Soo Kyung Kim, Chang Beom Lee, Sang Ho Jo, Tae Joon Cha, and Hyo Suk Ahn more...
- Subjects
Male ,medicine.medical_specialty ,Drug/Regimen ,Endocrinology, Diabetes and Metabolism ,Atorvastatin ,030209 endocrinology & metabolism ,030204 cardiovascular system & hematology ,Placebo ,Gastroenterology ,lcsh:Diseases of the endocrine glands. Clinical endocrinology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Double-Blind Method ,Diabetes mellitus ,Internal medicine ,Fatty Acids, Omega-3 ,medicine ,Humans ,Triglycerides ,Aged ,Hypertriglyceridemia ,lcsh:RC648-665 ,Triglyceride ,business.industry ,Cholesterol, HDL ,nutritional and metabolic diseases ,Cholesterol, LDL ,Middle Aged ,medicine.disease ,Eicosapentaenoic acid ,chemistry ,Tolerability ,Linear Models ,lipids (amino acids, peptides, and proteins) ,Original Article ,Female ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,business ,Dyslipidemia ,medicine.drug - Abstract
Background: Cardiovascular risk remains increased despite optimal low density lipoprotein cholesterol (LDL-C) level induced by intensive statin therapy. Therefore, recent guidelines recommend non-high density lipoprotein cholesterol (non-HDL-C) as a secondary target for preventing cardiovascular events. The aim of this study was to assess the efficacy and tolerability of omega-3 fatty acids (OM3-FAs) in combination with atorvastatin compared to atorvastatin alone in patients with mixed dyslipidemia. Methods: This randomized, double-blind, placebo-controlled, parallel-group, and phase III multicenter study included adults with fasting triglyceride (TG) levels ≥200 and more...
- Published
- 2019
34. Differential cutoff points and clinical impact of stent parameters of various drug-eluting stents for predicting major adverse clinical events: An individual patient data pooled analysis of seven stent-specific registries and 17,068 patients
- Author
-
Duk-Woo Park, Seung-Whan Lee, Jung-Min Ahn, Seung-Woon Rha, Do-Yoon Kang, Iris-Des Registry Investigators, Ki-Bae Seung, Seung Ho Hur, Cheol Hyun Lee, Kee-Sik Kim, Minkyu Han, Sung-Ho Her, Seong-Wook Park, Seung-Jung Park, and Pil-Hyung Lee more...
- Subjects
Data Analysis ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,030204 cardiovascular system & hematology ,Revascularization ,Coronary artery disease ,03 medical and health sciences ,0302 clinical medicine ,Predictive Value of Tests ,Humans ,Medicine ,Cutoff ,Prospective Studies ,Registries ,cardiovascular diseases ,030212 general & internal medicine ,Myocardial infarction ,Aged ,business.industry ,Stent ,Percutaneous coronary intervention ,Drug-Eluting Stents ,Middle Aged ,equipment and supplies ,medicine.disease ,Clinical trial ,surgical procedures, operative ,Cardiovascular Diseases ,Conventional PCI ,Female ,Radiology ,Cardiology and Cardiovascular Medicine ,business ,Follow-Up Studies - Abstract
Background Stent parameters (length and diameter) are well-known risk factors for adverse outcomes after percutaneous coronary intervention (PCI) with stenting. This study aimed to investigate the differential cutoff criteria and clinical impact of the length and diameter of various drug-eluting stents (DES) for predicting major cardiovascular events. Methods Using patient-level data from seven stent-specific, prospective DES registries, we evaluated 17,068 patients who underwent PCI with either various contemporary DES or first-generation DES between July 2007 and July 2015: 3053 treated with cobalt-chromium everolimus-eluting stents (CoCr-EES), 2976 with platinum-chromium EES (PtCr-EES), 2888 with Resolute zotarolimus-eluting stents (Re-ZES), 782 with Biomatrix biolimus-eluting stents (Bi-BES), 1868 with Nobori BES (No-BES), 1934 with Xience Prime cobalt-chromium EES (Pr-CoCr-EES), and 3567 with first-generation sirolimus-eluting stents (SES). Two clinical outcomes were assessed: target-vessel failure (TVF; a composite of cardiac death, target-vessel myocardial infarction, and target-vessel revascularization [TVR]) and TVR. Results Stent length and stent diameter were important factors for predicting TVF or TVR in the entire cohort and in each DES cohort. For TVF risk prediction, the Youden index-based cutoff of stent length was highest with Bi-BES (45.0 mm) and lowest with No-BES (29.0 mm), and the cutoff of stent diameter was smallest with Pr-CoCr-EES (2.78 mm) and largest with No-BES (3.20 mm). For TVR risk prediction, the cutoff of stent length was the highest with PtCr-EES (48.0 mm) and the lowest with No-BES (29.0 mm), and the cutoff of stent diameter was smallest with CoCr-EES (2.72 mm) and largest with first-generation SES (3.30 mm). The 3-year TVF and TVR rates were substantially different according to the presence or absence of long lesions and small vessels determined using these cutoff points. Conclusions For contemporary PCI practice involving diverse types of DES, we identified differential cutoff points of stent length and diameter for predicting adverse clinical outcomes. The clinical impact of these stent parameters on outcomes and its magnitude varied according to different DES. Clinical Trial Registration—URL: http://www.clinicaltrials.gov . Unique identifier: NCT01186133 . more...
- Published
- 2019
- Full Text
- View/download PDF
35. Randomized Trial Evaluating Percutaneous Coronary Intervention for the Treatment of Chronic Total Occlusion
- Author
-
Si Wan Choi, Wasan Udayachalerm, Toshiya Muramatsu, Yasushi Asakura, Sung Cheol Yun, Nae Hee Lee, Sang Wook Lim, Young-Hak Kim, Sang-Gon Lee, Bong-Ki Lee, Duk-Woo Park, Cheol Whan Lee, David Cohen, Seong Wook Park, Shirish Hiremath, Sung Ho Her, Pil Hyung Lee, Moo Hyun Kim, Seungbong Han, Soo Jin Kang, Hee Jun Kang, Seung-Woon Rha, Jong Young Lee, Seung-Whan Lee, Jung-Min Ahn, Sang Sig Cheong, Young Keun Ahn, Seung Ho Hur, Teguh Santoso, Etsuo Tsuchikane, Seung-Jung Park, and Jun Jack Cheng more...
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Percutaneous coronary intervention ,Total occlusion ,Surgery ,law.invention ,surgical procedures, operative ,Randomized controlled trial ,law ,Physiology (medical) ,Conventional PCI ,Arterial Occlusive Diseases ,Medicine ,cardiovascular diseases ,Cardiology and Cardiovascular Medicine ,business - Abstract
Background: Procedural results for percutaneous coronary intervention (PCI) in coronary vessels with chronic total occlusion (CTO) have improved in recent years, and PCI strategies have moved toward more complete revascularization with more liberal use of CTO-PCI. However, evidence evaluating CTO-PCI is limited to observational studies and small clinical trials. Methods: In this open-label, multicenter, randomized, noninferiority trial, PCI-eligible patients were assigned to receive either 1 of 2 strategies: PCI or no PCI for the qualifying de novo CTO lesion with the option for PCI of obstructive non-CTO lesions at the discretion of the operator. The primary end point was a composite of death, myocardial infarction, stroke, or any revascularization. Health-related quality of life was assessed at baseline and at 1, 6, 12, 24, and 36 months. Because of slow recruitment, the trial was stopped before completion of the 1284 planned enrollments. Results: Between March 2010 and September 2016, 834 patients were randomly assigned to the CTO-PCI (n=417) or no CTO-PCI (n=398) strategy. Among the patients assigned to the no CTO-PCI strategy, 78 (19.6%) crossed over to receive staged CTO-PCI within 3 days of randomization. The overall CTO-PCI success rate was 90.6%. Serious nonfatal complications associated with CTO-PCI occurred in 3 patients (1 stroke, 1 cardiac tamponade, and 1 patient with recurrent episodes of ventricular tachyarrhythmia induced by intracoronary thrombus). Approximately half of the patients in each group underwent PCI for an average of 1.3 non-CTO lesions, resulting in a comparable residual SYNTAX score (Synergy Between PCI With TAXUS and Cardiac Surgery; 3.7±5.4 versus 4.0±5.9, P =0.42) confined to non-CTO vessels. During a median follow-up of 4.0 years (interquartile range, 2.4 to 5.1 years), there was no significant difference between the CTO-PCI and the no CTO-PCI strategies in the incidence of the primary end point (22.3% versus 22.4%, hazard ratio, 1.03; 95% CI, 0.77 to 1.37; P =0.86). Both CTO-PCI and no CTO-PCI strategy were associated with significant improvements but without between-group differences in disease-specific health status that was sustained through 36 months. Conclusions: CTO-PCI was feasible with high success rates. There was no difference in the incidence of major adverse cardiovascular events with CTO-PCI versus no CTO-PCI, but the study was limited by low power for clinical end points and high crossover rates between groups. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01078051. more...
- Published
- 2019
- Full Text
- View/download PDF
36. Prognostic Impact of Periprocedural Myocardial Infarction in Patients with Heavily Calcified Coronary Artery Disease Receiving Rotational Atherectomy.
- Author
-
Jin Jung, Sung-Ho Her, Kyusup Lee, Ki-Dong Yoo, Keon-Woong Moon, Donggyu Moon, Su Nam Lee, Won Young Jang, Ik Jun Choi, Jae-Hwan Lee, Jang Hoon Lee, Sang Rok Lee, Seung-Whan Lee, Kyeong Ho Yun, and Hyun-Jong Lee more...
- Abstract
Background: Periprocedural myocardial infarction (PMI) occurs more frequently in patients with heavily calcified lesion and undergoing rotational atherectomy (RA). However, there are limited studies addressing prognostic impact of PMI in patients requiring RA due to severe coronary artery calcification (CAC). Therefore, the objective of this study was to determine the prognostic impact of PMI in patients who underwent percutaneous coronary intervention (PCI) using RA. Methods: A total of 540 patients (583 lesions) who received PCI using RA were enrolled between January 2010 and October 2019. PMI was defined as elevations of creatine kinase-myocardial band (CK-MB) >10 times the upper limited normal. Patients were divided into a PMI group and a non-PMI group. Primary endpoint was major adverse cardiovascular and cerebrovascular event (MACCE), a composite of cardiac death, target-vessel myocardial infarction, target-vessel revascularization, and cerebrovascular accident. Results: Although in-hospital events occurred more frequently in the PMI group than in the non-PMI group (15 [3.0%] vs. 6 [13.3%], p = 0.005), the incidence of MACCEs at 1 month, 1-12 months, or 12 months failed to show a significant difference between the two groups (1 month, 10 [2.0%] vs. 1 [2.2%], p > 0.999; 1-12 months, 39 [7.9%] vs. 7 [15.6%], p = 0.091; 12 months, 49 [9.9%] vs. 8 [17.8%], p = 0.123). Conclusions: This study shows that PMI after RA in patients with severe CAC was associated with more frequent in-hospital events and a nonsignificant trend for more events during 1 year follow-up. [ABSTRACT FROM AUTHOR] more...
- Published
- 2023
- Full Text
- View/download PDF
37. Clinical Outcome of Rotational Atherectomy in Calcified Lesions in Korea-ROCK Registry
- Author
-
Jae-Hwan Lee, Seung-Whan Lee, Kyeong-Ho Yun, Sung-Ho Her, Dae-Won Kim, Mahn-Won Park, Myunhee Lee, Sang-Rok Lee, Ki-Dong Yoo, Kyusup Lee, Hyun-Jong Lee, Pil-Hyung Lee, Jang Hoon Lee, Ji Hoon Jung, and Ik Jun Choi more...
- Subjects
Atherectomy, Coronary ,Male ,medicine.medical_specialty ,Medicine (General) ,medicine.medical_treatment ,clinical outcome ,Coronary Artery Disease ,030204 cardiovascular system & hematology ,Revascularization ,Article ,03 medical and health sciences ,0302 clinical medicine ,R5-920 ,Internal medicine ,Republic of Korea ,medicine ,Clinical endpoint ,drug-eluting stent ,Humans ,030212 general & internal medicine ,Myocardial infarction ,Registries ,Vascular Calcification ,rotational atherectomy ,Aged ,Retrospective Studies ,Ejection fraction ,business.industry ,Hazard ratio ,percutaneous coronary intervention ,Percutaneous coronary intervention ,Drug-Eluting Stents ,General Medicine ,medicine.disease ,Treatment Outcome ,Drug-eluting stent ,Conventional PCI ,business - Abstract
Background and Objectives: Data is still limited regarding clinical outcomes of rotational atherectomy (RA) after percutaneous coronary intervention. We sought to evaluate clinical outcomes of RA. Materials and Methods: This multi-center registry enrolled patients who underwent RA during PCI from nine tertiary centers in Korea between January 2010 and October 2019. The primary endpoint was target-vessel failure (TVF, the composite outcome of cardiac death, target-vessel spontaneous myocardial infarction, or target-vessel revascularization). Results: Of 540 patients (583 lesions), the mean patient age was 71.4 ± 0.4 years, 323 patients (59.8%) were men, and 305 patients (56.5%) had diabetes mellitus. Technical success rate was 96.4%. In-hospital major adverse cerebral and cardiac events occurred in 63 cases (10.8%). At 1.5 years, 72 (16.0%) of TVFs were occurred. We evaluated independent predictors of TVF, which included current smoker (hazard ratio (HR), 1.92, 95% confidence interval (CI), 1.17–3.16, p = 0.01), chronic renal disease (HR, 1.87, 95% CI, 1.14–3.08, p = 0.013), history of cerebrovascular attack (HR, 2.14, 95% CI, 1.24-3.68, p = 0.006), left ventricle ejection fraction (HR, 0.98, 95% CI, 0.97–0.999, p = 0.037), and left main disease (HR, 1.94, 95% CI, 1.11–3.37, p = 0.019). Conclusions: From this registry, we demonstrated acceptable success rates, in-hospital and mid-term clinical outcomes of RA in the DES era. more...
- Published
- 2021
38. Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation. the GLORIA-AF registry
- Author
-
George Ntaios, Menno V. Huisman, Hans-Christoph Diener, Jonathan L. Halperin, Christine Teutsch, Sabrina Marler, Venkatesh K. Gurusamy, Milla Thompson, Gregory Y.H. Lip, Brian Olshansky, Dzifa Wosornu Abban, Nasser Abdul, Atilio Marcelo Abud, Fran Adams, Srinivas Addala, Pedro Adragão, Walter Ageno, Rajesh Aggarwal, Sergio Agosti, Piergiuseppe Agostoni, Francisco Aguilar, Julio Aguilar Linares, Luis Aguinaga, Jameel Ahmed, Allessandro Aiello, Paul Ainsworth, Jorge Roberto Aiub, Raed Al-Dallow, Lisa Alderson, Jorge Antonio Aldrete Velasco, Dimitrios Alexopoulos, Fernando Alfonso Manterola, Pareed Aliyar, David Alonso, Fernando Augusto Alves da Costa, José Amado, Walid Amara, Mathieu Amelot, Nima Amjadi, Fabrizio Ammirati, Marianna Andrade, Nabil Andrawis, Giorgio Annoni, Gerardo Ansalone, M.Kevin Ariani, Juan Carlos Arias, Sébastien Armero, Chander Arora, Muhammad Shakil Aslam, M. Asselman, Philippe Audouin, Charles Augenbraun, S. Aydin, Ivaneta Ayryanova, Emad Aziz, Luciano Marcelo Backes, E. Badings, Ermentina Bagni, Seth H. Baker, Richard Bala, Antonio Baldi, Shigenobu Bando, Subhash Banerjee, Alan Bank, Gonzalo Barón Esquivias, Craig Barr, Maria Bartlett, Vanja Basic Kes, Giovanni Baula, Steffen Behrens, Alan Bell, Raffaella Benedetti, Juan Benezet Mazuecos, Bouziane Benhalima, Jutta Bergler-Klein, Jean-Baptiste Berneau, Richard A. Bernstein, Percy Berrospi, Sergio Berti, Andrea Berz, Elizabeth Best, Paulo Bettencourt, Robert Betzu, Ravi Bhagwat, Luna Bhatta, Francesco Biscione, Giovanni BISIGNANI, Toby Black, Michael J. Bloch, Stephen Bloom, Edwin Blumberg, Mario Bo, Ellen Bøhmer, Andreas Bollmann, Maria Grazia Bongiorni, Giuseppe Boriani, D.J. Boswijk, Jochen Bott, Edo Bottacchi, Marica Bracic Kalan, Drew Bradman, Donald Brautigam, Nicolas Breton, P.J.A.M. Brouwers, Kevin Browne, Jordi Bruguera Cortada, A. Bruni, Claude Brunschwig, Hervé Buathier, Aurélie Buhl, John Bullinga, Jose Walter Cabrera, Alberto Caccavo, Shanglang Cai, Sarah Caine, Leonardo Calò, Valeria Calvi, Mauricio Camarillo Sánchez, Rui Candeias, Vincenzo Capuano, Alessandro Capucci, Ronald Caputo, Tatiana Cárdenas Rizo, Francisco Cardona, Francisco Carlos da Costa Darrieux, Yan Carlos Duarte Vera, Antonio Carolei, Susana Carreño, Paula Carvalho, Susanna Cary, Gavino Casu, Claudio Cavallini, Guillaume Cayla, Aldo Celentano, Tae-Joon Cha, Kwang Soo Cha, Jei Keon Chae, Kathrine Chalamidas, Krishnan Challappa, Sunil Prakash Chand, Harinath Chandrashekar, Ludovic Chartier, Kausik Chatterjee, Carlos Antero Chavez Ayala, Aamir Cheema, Amjad Cheema, Lin Chen, Shih-Ann Chen, Jyh Hong Chen, Fu-Tien Chiang, Francesco Chiarella, Lin Chih-Chan, Yong Keun Cho, Jong-Il Choi, Dong Ju Choi, Guy Chouinard, Danny Hoi-Fan Chow, Dimitrios Chrysos, Galina Chumakova, Eduardo Julián José Roberto Chuquiure Valenzuela, Nicoleta Cindea Nica, David J. Cislowski, Anthony Clay, Piers Clifford, Andrew Cohen, Michael Cohen, Serge Cohen, Furio Colivicchi, Ronan Collins, Paolo Colonna, Steve Compton, Derek Connolly, Alberto Conti, Gabriel Contreras Buenostro, Gregg Coodley, Martin Cooper, Julian Coronel, Giovanni Corso, Juan Cosín Sales, Yves Cottin, John Covalesky, Aurel Cracan, Filippo Crea, Peter Crean, James Crenshaw, Tina Cullen, Harald Darius, Patrick Dary, Olivier Dascotte, Ira Dauber, Vicente Davalos, Ruth Davies, Gershan Davis, Jean-Marc Davy, Mark Dayer, Marzia De Biasio, Silvana De Bonis, Raffaele De Caterina, Teresiano De Franceschi, J.R. de Groot, José De Horta, Axel De La Briolle, Gilberto de la Pena Topete, Angelo Amato Vicenzo de Paola, Weimar de Souza, A. de Veer, Luc De Wolf, Eric Decoulx, Sasalu Deepak, Pascal Defaye, Freddy Del-Carpio Munoz, Diana Delic Brkljacic, N. Joseph Deumite, Silvia Di Legge, Igor Diemberger, Denise Dietz, Pedro Dionísio, Qiang Dong, Fabio Rossi dos Santos, Elena Dotcheva, Rami Doukky, Anthony D'Souza, Simon Dubrey, Xavier Ducrocq, Dmitry Dupljakov, Mauricio Duque, Dipankar Dutta, Nathalie Duvilla, A. Duygun, Rainer Dziewas, Charles B. Eaton, William Eaves, L.A. Ebels-Tuinbeek, Clifford Ehrlich, Sabine Eichinger-Hasenauer, Steven J. Eisenberg, Adnan El Jabali, Mahfouz El Shahawy, Mauro Esteves Hernandes, Ana Etxeberria Izal, Rudolph Evonich, Oksana Evseeva, Andrey Ezhov, Raed Fahmy, Quan Fang, Ramin Farsad, Laurent Fauchier, Stefano Favale, Maxime Fayard, Jose Luis Fedele, Francesco Fedele, Olga Fedorishina, Steven R. Fera, Luis Gustavo Gomes Ferreira, Jorge Ferreira, Claudio Ferri, Anna Ferrier, Hugo Ferro, Alexandra Finsen, Brian First, Stuart Fischer, Catarina Fonseca, Luísa Fonseca Almeida, Steven Forman, Brad Frandsen, William French, Keith Friedman, Athena Friese, Ana Gabriela Fruntelata, Shigeru Fujii, Stefano Fumagalli, Marta Fundamenski, Yutaka Furukawa, Matthias Gabelmann, Nashwa Gabra, Niels Gadsbøll, Michel Galinier, Anders Gammelgaard, Priya Ganeshkumar, Christopher Gans, Antonio Garcia Quintana, Olivier Gartenlaub, Achille Gaspardone, Conrad Genz, Frédéric Georger, Jean-Louis Georges, Steven Georgeson, Evaldas Giedrimas, Mariusz Gierba, Ignacio Gil Ortega, Eve Gillespie, Alberto Giniger, Michael C. Giudici, Alexandros Gkotsis, Taya V. Glotzer, Joachim Gmehling, Jacek Gniot, Peter Goethals, Seth Goldbarg, Ronald Goldberg, Britta Goldmann, Sergey Golitsyn, Silvia Gómez, Juan Gomez Mesa, Vicente Bertomeu Gonzalez, Jesus Antonio Gonzalez Hermosillo, Víctor Manuel González López, Hervé Gorka, Charles Gornick, Diana Gorog, Venkat Gottipaty, Pascal Goube, Ioannis Goudevenos, Brett Graham, G. Stephen Greer, Uwe Gremmler, Paul G. Grena, Martin Grond, Edoardo Gronda, Gerian Grönefeld, Xiang Gu, Ivett Guadalupe Torres Torres, Gabriele Guardigli, Carolina Guevara, Alexandre Guignier, Michele Gulizia, Michael Gumbley, Albrecht Günther, Andrew Ha, Georgios Hahalis, Joseph Hakas, Christian Hall, Bing Han, Seongwook Han, Joe Hargrove, David Hargroves, Kenneth B. Harris, Tetsuya Haruna, Emil Hayek, Jeff Healey, Steven Hearne, Michael Heffernan, Geir Heggelund, J.A. Heijmeriks, Maarten Hemels, I. Hendriks, Sam Henein, Sung-Ho Her, Paul Hermany, Jorge Eduardo Hernández Del Río, Yorihiko Higashino, Michael Hill, Tetsuo Hisadome, Eiji Hishida, Etienne Hoffer, Matthew Hoghton, Kui Hong, Suk keun Hong, Stevie Horbach, Masataka Horiuchi, Yinglong Hou, Jeff Hsing, Chi-Hung Huang, David Huckins, null kathy Hughes, A. Huizinga, E.L. Hulsman, Kuo-Chun Hung, Gyo-Seung Hwang, Margaret Ikpoh, Davide Imberti, Hüseyin Ince, Ciro Indolfi, Shujiro Inoue, Didier Irles, Harukazu Iseki, C. Noah Israel, Bruce Iteld, Venkat Iyer, Ewart Jackson-Voyzey, Naseem Jaffrani, Frank Jäger, Martin James, Sung-Won Jang, Nicolas Jaramillo, Nabil Jarmukli, Robert J. Jeanfreau, Ronald D. Jenkins, Carlos Jerjes Sánchez, Javier Jimenez, Robert Jobe, Tomas Joen-Jakobsen, Nicholas Jones, Jose Carlos Moura Jorge, Bernard Jouve, Byung Chun Jung, Kyung Tae Jung, Werner Jung, Mikhail Kachkovskiy, Krystallenia Kafkala, Larisa Kalinina, Bernd Kallmünzer, Farzan Kamali, Takehiro Kamo, Priit Kampus, Hisham Kashou, Andreas Kastrup, Apostolos Katsivas, Elizabeth Kaufman, Kazuya Kawai, Kenji Kawajiri, John F. Kazmierski, P. Keeling, José Francisco Kerr Saraiva, Galina Ketova, AJIT Singh Khaira, Aleksey Khripun, Doo-Il Kim, Young Hoon Kim, Nam Ho Kim, Dae Kyeong Kim, Jeong Su Kim, June Soo Kim, Ki Seok Kim, Jin bae Kim, Elena Kinova, Alexander Klein, James J. Kmetzo, G. Larsen Kneller, Aleksandar Knezevic, Su Mei Angela Koh, Shunichi Koide, Anastasios Kollias, J.A. Kooistra, Jay Koons, Martin Koschutnik, William J. Kostis, Dragan Kovacic, Jacek Kowalczyk, Natalya Koziolova, Peter Kraft, Johannes A. Kragten, Mori Krantz, Lars Krause, B.J. Krenning, F. Krikke, Z. Kromhout, Waldemar Krysiak, Priya Kumar, Thomas Kümler, Malte Kuniss, Jen-Yuan Kuo, Achim Küppers, Karla Kurrelmeyer, Choong Hwan Kwak, Bénédicte Laboulle, Arthur Labovitz, Wen Ter Lai, Andy Lam, Yat Yin Lam, Fernando Lanas Zanetti, Charles Landau, Giancarlo Landini, Estêvão Lanna Figueiredo, Torben Larsen, Karine Lavandier, Jessica LeBlanc, Moon Hyoung Lee, Chang-Hoon Lee, John Lehman, Ana Leitão, Nicolas Lellouche, Malgorzata Lelonek, Radoslaw Lenarczyk, T. Lenderink, Salvador León González, Peter Leong-Sit, Matthias Leschke, Nicolas Ley, Zhanquan Li, Xiaodong Li, Weihua Li, Xiaoming Li, Christhoh Lichy, Ira Lieber, Ramon Horacio Limon Rodriguez, Hailong Lin, Feng Liu, Hengliang Liu, Guillermo Llamas Esperon, Nassip Llerena Navarro, Eric Lo, Sergiy Lokshyn, Amador López, José Luís López-Sendón, Adalberto Menezes Lorga Filho, Richard S. Lorraine, Carlos Alberto Luengas, Robert Luke, Ming Luo, Steven Lupovitch, Philippe Lyrer, Changsheng Ma, Genshan Ma, Irene Madariaga, Koji Maeno, Dominique Magnin, Gustavo Maid, Sumeet K. Mainigi, Konstantinos Makaritsis, Rohit Malhotra, Rickey Manning, Athanasios Manolis, Helard Andres Manrique Hurtado, Ioannis Mantas, Fernando Manzur Jattin, Vicky Maqueda, Niccolo Marchionni, Francisco Marin Ortuno, Antonio Martín Santana, Jorge Martinez, Petra Maskova, Norberto Matadamas Hernandez, Katsuhiro Matsuda, Tillmann Maurer, Ciro Mauro, Erik May, Nolan Mayer, John McClure, Terry McCormack, William McGarity, Hugh McIntyre, Brent McLaurin, Feliz Alvaro Medina Palomino, Francesco Melandri, Hiroshi Meno, Dhananjai Menzies, Marco Mercader, Christian Meyer, Beat j. Meyer, Jacek Miarka, Frank Mibach, Dominik Michalski, Patrik Michel, Rami Mihail Chreih, Ghiath Mikdadi, Milan Mikus, Davor Milicic, Constantin Militaru, Sedi Minaie, Bogdan Minescu, Iveta Mintale, Tristan Mirault, Michael J. Mirro, Dinesh Mistry, Nicoleta Violeta Miu, Naomasa Miyamoto, Tiziano Moccetti, Akber Mohammed, Azlisham Mohd Nor, Michael Mollerus, Giulio Molon, Sergio Mondillo, Patrícia Moniz, Lluis Mont, Vicente Montagud, Oscar Montaña, Cristina Monti, Luciano Moretti, Kiyoo Mori, Andrew Moriarty, Jacek Morka, Luigi Moschini, Nikitas Moschos, Andreas Mügge, Thomas J. Mulhearn, Carmen Muresan, Michela Muriago, Wlodzimierz Musial, Carl W. Musser, Francesco Musumeci, Thuraia Nageh, Hidemitsu Nakagawa, Yuichiro Nakamura, Toru Nakayama, Gi-Byoung Nam, Michele Nanna, Indira Natarajan, Hemal M. Nayak, Stefan Naydenov, Jurica Nazli, Alexandru Cristian Nechita, Libor Nechvatal, Sandra Adela Negron, James Neiman, Fernando Carvalho Neuenschwander, David Neves, Anna Neykova, Ricardo Nicolás Miguel, George Nijmeh, Alexey Nizov, Rodrigo Noronha Campos, Janko Nossan, Tatiana Novikova, Ewa Nowalany-Kozielska, Emmanuel Nsah, Juan Carlos Nunez Fragoso, Svetlana Nurgalieva, Dieter Nuyens, Ole Nyvad, Manuel Odin de Los Rios Ibarra, Philip O'Donnell, Martin O'Donnell, Seil Oh, Yong Seog Oh, Dongjin Oh, Gilles O'Hara, Kostas Oikonomou, Claudia Olivares, Richard Oliver, Rafael Olvera Ruiz, Christoforos Olympios, null Anna omaszuk-Kazberuk, Joaquín Osca Asensi, null eena Padayattil jose, Francisco Gerardo Padilla Padilla, Victoria Padilla Rios, Giuseppe Pajes, A. Shekhar Pandey, Gaetano Paparella, F. Paris, Hyung Wook Park, Jong Sung Park, Fragkiskos Parthenakis, Enrico Passamonti, Rajesh J. Patel, Jaydutt Patel, Mehool Patel, Janice Patrick, Ricardo Pavón Jimenez, Analía Paz, Vittorio Pengo, William Pentz, Beatriz Pérez, Alma Minerva Pérez Ríos, Alejandro Pérez-Cabezas, Richard Perlman, Viktor Persic, Francesco Perticone, Terri K. Peters, Sanjiv Petkar, Luis Felipe Pezo, Christian Pflücke, David N. Pham, Roland T. Phillips, Stephen Phlaum, Denis Pieters, Julien Pineau, Arnold Pinter, Fausto Pinto, R. Pisters, Nediljko Pivac, Darko Pocanic, Cristian Podoleanu, Alessandro Politano, Zdravka Poljakovic, Stewart Pollock, Jose Polo Garcéa, Holger Poppert, Maurizio Porcu, Antonio Pose Reino, Neeraj Prasad, Dalton Bertolim Précoma, Alessandro Prelle, John Prodafikas, Konstantin Protasov, Maurice Pye, Zhaohui Qiu, Jean-Michel Quedillac, Dimitar Raev, Carlos Antonio Raffo Grado, Sidiqullah Rahimi, Arturo Raisaro, Bhola Rama, Ricardo Ramos, Maria Ranieri, Nuno Raposo, Eric Rashba, Ursula Rauch-Kroehnert, Ramakota Reddy, Giulia Renda, Shabbir Reza, Luigi Ria, Dimitrios Richter, Hans Rickli, Werner Rieker, Tomas Ripolil Vera, Luiz Eduardo Ritt, Douglas Roberts, Ignacio Rodriguez Briones, Aldo Edwin Rodriguez Escudero, Carlos Rodríguez Pascual, Mark Roman, Francesco Romeo, E. Ronner, Jean-Francois Roux, Nadezda Rozkova, Miroslav Rubacek, Frank Rubalcava, Andrea M. Russo, Matthieu Pierre Rutgers, Karin Rybak, Samir Said, Tamotsu Sakamoto, Abraham Salacata, Adrien Salem, Rafael Salguero Bodes, Marco A. Saltzman, Alessandro Salvioni, Gregorio Sanchez Vallejo, Marcelo Sanmartín Fernández, Wladmir Faustino Saporito, Kesari Sarikonda, Taishi Sasaoka, Hamdi Sati, Irina Savelieva, Pierre-Jean Scala, Peter Schellinger, Carlos Scherr, Lisa Schmitz, Karl-Heinz Schmitz, Bettina Schmitz, Teresa Schnabel, Steffen Schnupp, Peter Schoeniger, Norbert Schön, Peter Schwimmbeck, Clare Seamark, Greg Searles, Karl-Heinz Seidl, Barry Seidman, Jaroslaw Sek, Lakshmanan Sekaran, Carlo SERRATI, Neerav Shah, Vinay Shah, Anil Shah, Shujahat Shah, Vijay Kumar Sharma, Louise Shaw, Khalid H. Sheikh, Naruhito Shimizu, Hideki Shimomura, Dong-Gu Shin, Eun-Seok Shin, Junya Shite, Gerolamo Sibilio, Frank Silver, Iveta Sime, Tim A. Simmers, Narendra Singh, Peter Siostrzonek, Didier Smadja, David W. Smith, Marcelo Snitman, Dario Sobral Filho, Hassan Soda, Carl Sofley, Adam Sokal, Yannie Soo Oi Yan, Rodolfo Sotolongo, Olga Ferreira de Souza, Jon Arne Sparby, Jindrich Spinar, David Sprigings, Alex C. Spyropoulos, Dimitrios Stakos, Clemens Steinwender, George Stergiou, Ian Stiell, Marcus Stoddard, Anastas Stoikov, Witold Streb, Ioannis Styliadis, Guohai Su, Xi Su, Wanda Sudnik, Kai Sukles, Xiaofei Sun, H. Swart, Janko Szavits-Nossan, Jens Taggeselle, Yuichiro Takagi, Amrit Pal Singh Takhar, Angelika Tamm, Katsumi Tanaka, Tanyanan Tanawuttiwat, Sherman Tang, Aylmer Tang, Giovanni Tarsi, Tiziana Tassinari, Ashis Tayal, Muzahir Tayebjee, J.M. ten Berg, Dan Tesloianu, Salem H.K. The, Dierk Thomas, Serge Timsit, Tetsuya Tobaru, Andrzej R. Tomasik, Mikhail Torosoff, Emmanuel Touze, Elina Trendafilova, W. Kevin Tsai, Hung Fat Tse, Hiroshi Tsutsui, Tian Ming Tu, Ype Tuininga, Minang Turakhia, Samir Turk, Wayne Tcurner, Arnljot Tveit, Richard Tytus, C. Valadão, P.F.M.M. van Bergen, Philippe van de Borne, B.J. van den Berg, C. van der Zwaan, M. Van Eck, Peter Vanacker, Dimo Vasilev, Vasileios Vasilikos, Maxim Vasilyev, Srikar Veerareddy, Mario Vega Miño, Asok Venkataraman, Paolo Verdecchia, Francesco Versaci, Ernst Günter Vester, Hubert Vial, Jason Victory, Alejandro Villamil, Marc Vincent, Anthony Vlastaris, Jürgen vom Dahl, Kishor Vora, Robert B. Vranian, Paul Wakefield, Ningfu Wang, Mingsheng Wang, Xinhua Wang, Feng Wang, Tian Wang, Alberta L. Warner, Kouki Watanabe, Jeanne Wei, Christian Weimar, Stanislav Weiner, Renate Weinrich, Ming-Shien Wen, Marcus Wiemer, Preben Wiggers, Andreas Wilke, David Williams, Marcus L. Williams, Bernhard Witzenbichler, Brian Wong, Ka Sing Lawrence Wong, Beata Wozakowska-Kaplon, Shulin Wu, Richard C. Wu, Silke Wunderlich, Nell Wyatt, John (Jack) Wylie, Yong Xu, Xiangdong Xu, Hiroki Yamanoue, Takeshi Yamashita, Ping Yen Bryan Yan, Tianlun Yang, Jing Yao, Kuo-Ho Yeh, Wei Hsian Yin, Yoto Yotov, Ralf Zahn, Stuart Zarich, Sergei Zenin, Elisabeth Louise Zeuthen, Huanyi Zhang, Donghui Zhang, Xingwei Zhang, Ping Zhang, Jun Zhang, Shui Ping Zhao, Yujie Zhao, Zhichen Zhao, Yang Zheng, Jing Zhou, Sergio Zimmermann, Andrea Zini, Steven Zizzo, Wenxia Zong, L Steven Zukerman, Cardiology, ACS - Heart failure & arrhythmias, Ntaios G., Huisman M.V., Diener H.-C., Halperin J.L., Teutsch C., Marler S., Gurusamy V.K., Thompson M., Lip G.Y.H., Olshansky B., Abban D.W., Abdul N., Abud A.M., Adams F., Addala S., Adragao P., Ageno W., Aggarwal R., Agosti S., Agostoni P., Aguilar F., Linares J.A., Aguinaga L., Ahmed J., Aiello A., Ainsworth P., Aiub J.R., Al-Dallow R., Alderson L., Aldrete Velasco J.A., Alexopoulos D., Manterola F.A., Aliyar P., Alonso D., Alves da Costa F.A., Amado J., Amara W., Amelot M., Amjadi N., Ammirati F., Andrade M., Andrawis N., Annoni G., Ansalone G., Ariani M.K., Arias J.C., Armero S., Arora C., Aslam M.S., Asselman M., Audouin P., Augenbraun C., Aydin S., Ayryanova I., Aziz E., Backes L.M., Badings E., Bagni E., Baker S.H., Bala R., Baldi A., Bando S., Banerjee S., Bank A., Esquivias G.B., Barr C., Bartlett M., Kes V.B., Baula G., Behrens S., Bell A., Benedetti R., Mazuecos J.B., Benhalima B., Bergler-Klein J., Berneau J.-B., Bernstein R.A., Berrospi P., Berti S., Berz A., Best E., Bettencourt P., Betzu R., Bhagwat R., Bhatta L., Biscione F., BISIGNANI G., Black T., Bloch M.J., Bloom S., Blumberg E., Bo M., Bohmer E., Bollmann A., Bongiorni M.G., Boriani G., Boswijk D.J., Bott J., Bottacchi E., Kalan M.B., Bradman D., Brautigam D., Breton N., Brouwers P.J.A.M., Browne K., Cortada J.B., Bruni A., Brunschwig C., Buathier H., Buhl A., Bullinga J., Cabrera J.W., Caccavo A., Cai S., Caine S., Calo L., Calvi V., Sanchez M.C., Candeias R., Capuano V., Capucci A., Caputo R., Rizo T.C., Cardona F., Carlos da Costa Darrieux F., Duarte Vera Y.C., Carolei A., Carreno S., Carvalho P., Cary S., Casu G., Cavallini C., Cayla G., Celentano A., Cha T.-J., Cha K.S., Chae J.K., Chalamidas K., Challappa K., Chand S.P., Chandrashekar H., Chartier L., Chatterjee K., Chavez Ayala C.A., Cheema A., Chen L., Chen S.-A., Chen J.H., Chiang F.-T., Chiarella F., Chih-Chan L., Cho Y.K., Choi J.-I., Choi D.J., Chouinard G., Hoi-Fan Chow D., Chrysos D., Chumakova G., Jose Roberto Chuquiure Valenzuela E.J., Nica N.C., Cislowski D.J., Clay A., Clifford P., Cohen A., Cohen M., Cohen S., Colivicchi F., Collins R., Colonna P., Compton S., Connolly D., Conti A., Buenostro G.C., Coodley G., Cooper M., Coronel J., Corso G., Sales J.C., Cottin Y., Covalesky J., Cracan A., Crea F., Crean P., Crenshaw J., Cullen T., Darius H., Dary P., Dascotte O., Dauber I., Davalos V., Davies R., Davis G., Davy J.-M., Dayer M., De Biasio M., De Bonis S., De Caterina R., De Franceschi T., de Groot J.R., De Horta J., De La Briolle A., Topete G.D.L.P., Vicenzo de Paola A.A., de Souza W., de Veer A., De Wolf L., Decoulx E., Deepak S., Defaye P., Del-Carpio Munoz F., Brkljacic D.D., Deumite N.J., Di Legge S., Diemberger I., Dietz D., Dionisio P., Dong Q., Rossi dos Santos F., Dotcheva E., Doukky R., D'Souza A., Dubrey S., Ducrocq X., Dupljakov D., Duque M., Dutta D., Duvilla N., Duygun A., Dziewas R., Eaton C.B., Eaves W., Ebels-Tuinbeek L.A., Ehrlich C., Eichinger-Hasenauer S., Eisenberg S.J., El Jabali A., El Shahawy M., Hernandes M.E., Izal A.E., Evonich R., Evseeva O., Ezhov A., Fahmy R., Fang Q., Farsad R., Fauchier L., Favale S., Fayard M., Fedele J.L., Fedele F., Fedorishina O., Fera S.R., Gomes Ferreira L.G., Ferreira J., Ferri C., Ferrier A., Ferro H., Finsen A., First B., Fischer S., Fonseca C., Almeida L.F., Forman S., Frandsen B., French W., Friedman K., Friese A., Fruntelata A.G., Fujii S., Fumagalli S., Fundamenski M., Furukawa Y., Gabelmann M., Gabra N., Gadsboll N., Galinier M., Gammelgaard A., Ganeshkumar P., Gans C., Quintana A.G., Gartenlaub O., Gaspardone A., Genz C., Georger F., Georges J.-L., Georgeson S., Giedrimas E., Gierba M., Ortega I.G., Gillespie E., Giniger A., Giudici M.C., Gkotsis A., Glotzer T.V., Gmehling J., Gniot J., Goethals P., Goldbarg S., Goldberg R., Goldmann B., Golitsyn S., Gomez S., Mesa J.G., Gonzalez V.B., Gonzalez Hermosillo J.A., Gonzalez Lopez V.M., Gorka H., Gornick C., Gorog D., Gottipaty V., Goube P., Goudevenos I., Graham B., Greer G.S., Gremmler U., Grena P.G., Grond M., Gronda E., Gronefeld G., Gu X., Torres Torres I.G., Guardigli G., Guevara C., Guignier A., Gulizia M., Gumbley M., Gunther A., Ha A., Hahalis G., Hakas J., Hall C., Han B., Han S., Hargrove J., Hargroves D., Harris K.B., Haruna T., Hayek E., Healey J., Hearne S., Heffernan M., Heggelund G., Heijmeriks J.A., Hemels M., Hendriks I., Henein S., Her S.-H., Hermany P., Hernandez Del Rio J.E., Higashino Y., Hill M., Hisadome T., Hishida E., Hoffer E., Hoghton M., Hong K., Hong S.K., Horbach S., Horiuchi M., Hou Y., Hsing J., Huang C.-H., Huckins D., kathy Hughe, Huizinga A., Hulsman E.L., Hung K.-C., Hwang G.-S., Ikpoh M., Imberti D., Ince H., Indolfi C., Inoue S., Irles D., Iseki H., Israel C.N., Iteld B., Iyer V., Jackson-Voyzey E., Jaffrani N., Jager F., James M., Jang S.-W., Jaramillo N., Jarmukli N., Jeanfreau R.J., Jenkins R.D., Sanchez C.J., Jimenez J., Jobe R., Joen-Jakobsen T., Jones N., Moura Jorge J.C., Jouve B., Jung B.C., Jung K.T., Jung W., Kachkovskiy M., Kafkala K., Kalinina L., Kallmunzer B., Kamali F., Kamo T., Kampus P., Kashou H., Kastrup A., Katsivas A., Kaufman E., Kawai K., Kawajiri K., Kazmierski J.F., Keeling P., Kerr Saraiva J.F., Ketova G., Khaira A.S., Khripun A., Kim D.-I., Kim Y.H., Kim N.H., Kim D.K., Kim J.S., Kim K.S., Kim J.B., Kinova E., Klein A., Kmetzo J.J., Kneller G.L., Knezevic A., Angela Koh S.M., Koide S., Kollias A., Kooistra J.A., Koons J., Koschutnik M., Kostis W.J., Kovacic D., Kowalczyk J., Koziolova N., Kraft P., Kragten J.A., Krantz M., Krause L., Krenning B.J., Krikke F., Kromhout Z., Krysiak W., Kumar P., Kumler T., Kuniss M., Kuo J.-Y., Kuppers A., Kurrelmeyer K., Kwak C.H., Laboulle B., Labovitz A., Lai W.T., Lam A., Lam Y.Y., Zanetti F.L., Landau C., Landini G., Figueiredo E.L., Larsen T., Lavandier K., LeBlanc J., Lee M.H., Lee C.-H., Lehman J., Leitao A., Lellouche N., Lelonek M., Lenarczyk R., Lenderink T., Gonzalez S.L., Leong-Sit P., Leschke M., Ley N., Li Z., Li X., Li W., Lichy C., Lieber I., Limon Rodriguez R.H., Lin H., Liu F., Liu H., Esperon G.L., Navarro N.L., Lo E., Lokshyn S., Lopez A., Lopez-Sendon J.L., Lorga Filho A.M., Lorraine R.S., Luengas C.A., Luke R., Luo M., Lupovitch S., Lyrer P., Ma C., Ma G., Madariaga I., Maeno K., Magnin D., Maid G., Mainigi S.K., Makaritsis K., Malhotra R., Manning R., Manolis A., Manrique Hurtado H.A., Mantas I., Jattin F.M., Maqueda V., Marchionni N., Ortuno F.M., Santana A.M., Martinez J., Maskova P., Hernandez N.M., Matsuda K., Maurer T., Mauro C., May E., Mayer N., McClure J., McCormack T., McGarity W., McIntyre H., McLaurin B., Medina Palomino F.A., Melandri F., Meno H., Menzies D., Mercader M., Meyer C., Meyer B.J., Miarka J., Mibach F., Michalski D., Michel P., Chreih R.M., Mikdadi G., Mikus M., Milicic D., Militaru C., Minaie S., Minescu B., Mintale I., Mirault T., Mirro M.J., Mistry D., Miu N.V., Miyamoto N., Moccetti T., Mohammed A., Nor A.M., Mollerus M., Molon G., Mondillo S., Moniz P., Mont L., Montagud V., Montana O., Monti C., Moretti L., Mori K., Moriarty A., Morka J., Moschini L., Moschos N., Mugge A., Mulhearn T.J., Muresan C., Muriago M., Musial W., Musser C.W., Musumeci F., Nageh T., Nakagawa H., Nakamura Y., Nakayama T., Nam G.-B., Nanna M., Natarajan I., Nayak H.M., Naydenov S., Nazli J., Nechita A.C., Nechvatal L., Negron S.A., Neiman J., Neuenschwander F.C., Neves D., Neykova A., Miguel R.N., Nijmeh G., Nizov A., Campos R.N., Nossan J., Novikova T., Nowalany-Kozielska E., Nsah E., Nunez Fragoso J.C., Nurgalieva S., Nuyens D., Nyvad O., Odin de Los Rios Ibarra M., O'Donnell P., O'Donnell M., Oh S., Oh Y.S., Oh D., O'Hara G., Oikonomou K., Olivares C., Oliver R., Ruiz R.O., Olympios C., Anna omaszuk-Kazberuk, Asensi J.O., eena Padayattil jose, Padilla Padilla F.G., Rios V.P., Pajes G., Pandey A.S., Paparella G., Paris F., Park H.W., Park J.S., Parthenakis F., Passamonti E., Patel R.J., Patel J., Patel M., Patrick J., Jimenez R.P., Paz A., Pengo V., Pentz W., Perez B., Perez Rios A.M., Perez-Cabezas A., Perlman R., Persic V., Perticone F., Peters T.K., Petkar S., Pezo L.F., Pflucke C., Pham D.N., Phillips R.T., Phlaum S., Pieters D., Pineau J., Pinter A., Pinto F., Pisters R., Pivac N., Pocanic D., Podoleanu C., Politano A., Poljakovic Z., Pollock S., Garcea J.P., Poppert H., Porcu M., Reino A.P., Prasad N., Precoma D.B., Prelle A., Prodafikas J., Protasov K., Pye M., Qiu Z., Quedillac J.-M., Raev D., Raffo Grado C.A., Rahimi S., Raisaro A., Rama B., Ramos R., Ranieri M., Raposo N., Rashba E., Rauch-Kroehnert U., Reddy R., Renda G., Reza S., Ria L., Richter D., Rickli H., Rieker W., Vera T.R., Ritt L.E., Roberts D., Briones I.R., Rodriguez Escudero A.E., Pascual C.R., Roman M., Romeo F., Ronner E., Roux J.-F., Rozkova N., Rubacek M., Rubalcava F., Russo A.M., Rutgers M.P., Rybak K., Said S., Sakamoto T., Salacata A., Salem A., Bodes R.S., Saltzman M.A., Salvioni A., Vallejo G.S., Fernandez M.S., Saporito W.F., Sarikonda K., Sasaoka T., Sati H., Savelieva I., Scala P.-J., Schellinger P., Scherr C., Schmitz L., Schmitz K.-H., Schmitz B., Schnabel T., Schnupp S., Schoeniger P., Schon N., Schwimmbeck P., Seamark C., Searles G., Seidl K.-H., Seidman B., Sek J., Sekaran L., SERRATI C., Shah N., Shah V., Shah A., Shah S., Sharma V.K., Shaw L., Sheikh K.H., Shimizu N., Shimomura H., Shin D.-G., Shin E.-S., Shite J., Sibilio G., Silver F., Sime I., Simmers T.A., Singh N., Siostrzonek P., Smadja D., Smith D.W., Snitman M., Filho D.S., Soda H., Sofley C., Sokal A., Oi Yan Y.S., Sotolongo R., Ferreira de Souza O., Sparby J.A., Spinar J., Sprigings D., Spyropoulos A.C., Stakos D., Steinwender C., Stergiou G., Stiell I., Stoddard M., Stoikov A., Streb W., Styliadis I., Su G., Su X., Sudnik W., Sukles K., Sun X., Swart H., Szavits-Nossan J., Taggeselle J., Takagi Y., Singh Takhar A.P., Tamm A., Tanaka K., Tanawuttiwat T., Tang S., Tang A., Tarsi G., Tassinari T., Tayal A., Tayebjee M., Berg J.M.T., Tesloianu D., The S.H.K., Thomas D., Timsit S., Tobaru T., Tomasik A.R., Torosoff M., Touze E., Trendafilova E., Tsai W.K., Tse H.F., Tsutsui H., Tu T.M., Tuininga Y., Turakhia M., Turk S., Tcurner W., Tveit A., Tytus R., Valadao C., van Bergen P.F.M.M., van de Borne P., van den Berg B.J., van der Zwaan C., Van Eck M., Vanacker P., Vasilev D., Vasilikos V., Vasilyev M., Veerareddy S., Mino M.V., Venkataraman A., Verdecchia P., Versaci F., Vester E.G., Vial H., Victory J., Villamil A., Vincent M., Vlastaris A., Dahl J.V., Vora K., Vranian R.B., Wakefield P., Wang N., Wang M., Wang X., Wang F., Wang T., Warner A.L., Watanabe K., Wei J., Weimar C., Weiner S., Weinrich R., Wen M.-S., Wiemer M., Wiggers P., Wilke A., Williams D., Williams M.L., Witzenbichler B., Wong B., Lawrence Wong K.S., Wozakowska-Kaplon B., Wu S., Wu R.C., Wunderlich S., Wyatt N., Wylie J.J., Xu Y., Xu X., Yamanoue H., Yamashita T., Bryan Yan P.Y., Yang T., Yao J., Yeh K.-H., Yin W.H., Yotov Y., Zahn R., Zarich S., Zenin S., Zeuthen E.L., Zhang H., Zhang D., Zhang X., Zhang P., Zhang J., Zhao S.P., Zhao Y., Zhao Z., Zheng Y., Zhou J., Zimmermann S., Zini A., Zizzo S., Zong W., and Zukerman L.S. more...
- Subjects
Oral ,medicine.medical_specialty ,anticoagulants ,Vitamin K ,medicine.drug_class ,Medizin ,Administration, Oral ,030204 cardiovascular system & hematology ,law.invention ,03 medical and health sciences ,Antithrombotic treatment ,0302 clinical medicine ,Randomized controlled trial ,law ,Risk Factors ,Internal medicine ,Antithrombotic ,medicine ,non-vitamin-K antagonist oral anticoagulant ,Diseases of the circulatory (Cardiovascular) system ,Humans ,SAMe-TT2R2 ,In patient ,atrial fibrillation ,030212 general & internal medicine ,Prospective Studies ,Registries ,Medical prescription ,business.industry ,Anticoagulant ,non-vitamin-K antagonist oral ,Atrial fibrillation ,medicine.disease ,non-vitamin-K antagonist oral anticoagulants ,Clinical trial ,Stroke ,Treatment Outcome ,SAMe-TT ,RC666-701 ,2 ,R ,vitamin-K-antagonist oral anticoagulants ,Administration ,Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE ,SAMe-TT R ,Cardiology and Cardiovascular Medicine ,business - Abstract
CA extern - Weitere Nicht-UDE-Autoren sind nicht genannt. Aim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores >2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in clinical practice, VKAs may be prescribed less frequently to patients with AF and SAMe-TT2R2 scores >2 than to patients with lower scores. Methods and results: We analyzed the Phase III dataset of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective global registry of patients with newly diagnosed AF and ≥1 stroke risk factor. We compared baseline clinical characteristics and antithrombotic prescriptions to determine the probability of the VKA prescription among anticoagulated patients with the baseline SAMe-TT2R2 score >2 and ≤ 2. Among 17,465 anticoagulated patients with AF, 4,828 (27.6%) patients were prescribed VKA and 12,637 (72.4%) patients an NOAC: 11,884 (68.0%) patients had SAMe-TT2R2 scores 0-2 and 5,581 (32.0%) patients had scores >2. The proportion of patients prescribed VKA was 28.0% among patients with SAMe-TT2R2 scores >2 and 27.5% in those with scores ≤2. Conclusions: The lack of a clear association between the SAMe-TT2R2 score and anticoagulant selection may be attributed to the relative efficacy and safety profiles between NOACs and VKAs as well as to the absence of trial evidence that an SAMe-TT2R2-guided strategy for the selection of the type of anticoagulation in NVAF patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized controlled trial. Clinical trial registration: URL: https://www.clinicaltrials.gov//Unique identifier: NCT01937377, NCT01468701, and NCT01671007. © 2020 Hellenic Society of Cardiology more...
- Published
- 2021
39. Multivessel versus IRA-only PCI in patients with NSTEMI and severe left ventricular systolic dysfunction
- Author
-
Kyusup Lee, Shung Chull Chae, Hyo-Soo Kim, Seok Kyu Oh, Kwang Soo Cha, Hyeon Cheol Gwon, Kwon-Bae Kim, Myunhee Lee, Kiyuk Chang, Sung-Ho Her, Dae-Won Kim, Myung Ho Jeong, Kamir-Nih registry investigators, Seung-Woon Rha, Kyung-Kuk Hwang, In Whan Seong, Jei Keon Chae, Mahn-Won Park, Ji Hoon Jung, Wook Sung Chung, and Young Jo Kim more...
- Subjects
Male ,Cardiovascular Procedures ,Epidemiology ,medicine.medical_treatment ,Myocardial Infarction ,Severity of Illness Index ,Ventricular Function, Left ,Ventricular Dysfunction, Left ,Risk Factors ,Medicine and Health Sciences ,Myocardial infarction ,Prospective Studies ,Registries ,Non-ST Elevated Myocardial Infarction ,Coronary Arteries ,Aged, 80 and over ,Multidisciplinary ,Ejection fraction ,Coronary Artery Bypass Grafting ,Hazard ratio ,Arteries ,Middle Aged ,Coronary Vessels ,Treatment Outcome ,Cardiovascular Diseases ,Cardiology ,Medicine ,Female ,Anatomy ,Research Article ,medicine.medical_specialty ,Science ,Surgical and Invasive Medical Procedures ,Lower risk ,Signs and Symptoms ,Percutaneous Coronary Intervention ,Internal medicine ,medicine ,Humans ,Vascular Diseases ,cardiovascular diseases ,Aged ,Proportional Hazards Models ,Coronary Revascularization ,business.industry ,Revascularization ,Angioplasty ,Percutaneous coronary intervention ,Biology and Life Sciences ,medicine.disease ,Confidence interval ,Medical Risk Factors ,Conventional PCI ,Lesions ,Cardiovascular Anatomy ,Blood Vessels ,Clinical Medicine ,business ,Coronary Angioplasty ,Mace - Abstract
BackgroundA substantial number of patients presenting with non-ST-elevation myocardial infarction (NSTEMI) and multivessel disease (MVD) have severe left ventricular systolic dysfunction (LVSD) (left ventricular ejection fraction (LVEF) less than 35%). But data are lacking regarding optimal percutaneous coronary intervention (PCI) strategy for these patients. The aim of this study was to compare the long-term outcomes of IRA (infarct-related artery)-only and multivessel PCI in patients with NSTEMI and MVD complicated by severe LVSD.MethodsAmong 13,104 patients enrolled in the PCI registry from November 2011 to December 2015, patients with NSTEMI and MVD with severe LVSD who underwent successful PCI were screened. The primary outcome was 3-year major adverse cardiovascular events (MACEs), defined as all-cause death, any myocardial infarction, stroke, and any revascularization.ResultsOverall, 228 patients were treated with IRA-only PCI (n = 104) or MV-PCI (n = 124). The MACE risk was significantly lower in the MV-PCI group than in the IRA-only PCI group (35.5% vs. 54.8%; hazard ratio [HR] 0.561; 95% confidence interval [CI] 0.378–0.832; p = 0.04). This result was mainly driven by a significantly lower risk of all-cause death (23.4% vs. 41.4%; hazard ratio [HR] 0.503; 95% confidence interval [CI] 0.314–0.806; p = 0.004). The results were consistent after multivariate regression, propensity-score matching, and inverse probability weighting to adjust for baseline differences.ConclusionsAmong patients with NSTEMI and MVD complicated with severe LVSD, multivessel PCI was associated with a significantly lower MACE risk. The findings may provide valuable information to physicians who are involved in decision-making for these patients. more...
- Published
- 2021
40. Prognostic Value of Estimated Glomerular Filtration Rate 3-6 Months after Percutaneous Coronary Intervention
- Author
-
Dong-Bin Kim, Wook Sung Chung, Chul Soo Park, Sung-Ho Her, Hee-Yeol Kim, Jongmin Lee, and Won Jik Lee
- Subjects
medicine.medical_specialty ,business.industry ,Urology ,medicine.medical_treatment ,Mortality rate ,Stent ,Percutaneous coronary intervention ,Renal function ,Drug-Eluting Stents ,Prognosis ,Normal renal function ,surgical procedures, operative ,Percutaneous Coronary Intervention ,Drug-eluting stent ,Conventional PCI ,Medicine ,Humans ,cardiovascular diseases ,Renal Insufficiency ,Cardiology and Cardiovascular Medicine ,business ,Clinical risk factor ,Glomerular Filtration Rate - Abstract
Background: The prognostic significance of follow-up (f/u) renal function for patients undergoing percutaneous coronary intervention (PCI) remains unknown. This study sought to investigate the prognostic implications of f/u renal function in patients undergoing PCI. Methods: A drug-eluting stent registry was used. We divided patients into 4 groups according to the change in the estimated glomerular filtration rate (eGFR) before PCI and 3–6 months after PCI. Patients with normal pre-PCI eGFR and f/u eGFR were assigned to group 1. Those with normal pre-PCI eGFR and abnormal f/u eGFR were assigned to group 2. Patients with abnormal pre-PCI eGFR and normal f/u eGFR were assigned to group 3. Patients with abnormal pre-PCI eGFR and f/u eGFR were allocated into group 4. Results: A total of 4,899 PCI patients were enrolled. The death rate in group 1, 2, 3, and 4 at 3 years was 2, 11, 4, and 9%, respectively. This showed significant differences between groups, except between groups 2 and 4. The prognosis of a group with aggravation from normal renal function was worse than that of a group with recovery from abnormal renal function. A prediction model that combines clinical risk factors and f/u eGFR has more power for predicting clinical outcomes than a combination of clinical risk factors and pre-PCI eGFR. Conclusion: Post-PCI eGFR was more accurate for predicting patient outcomes than pre-PCI eGFR. more...
- Published
- 2020
41. Comparison of successful percutaneous coronary intervention versus optimal medical therapy in patients with coronary chronic total occlusion
- Author
-
Dong-Bin Kim, Eun Ho Choo, Hee Yeol Kim, Sung Ho Her, Ki Dong Yoo, Yoon Seok Koh, Pum Joon Kim, Doo Soo Jeon, Kiyuk Chang, Ki Bae Seung, Chul Soo Park, Wook Sung Chung, Hun Jun Park, Jongmin Lee, and Suk Min Seo more...
- Subjects
Male ,medicine.medical_specialty ,Time Factors ,medicine.medical_treatment ,Population ,Subgroup analysis ,030204 cardiovascular system & hematology ,03 medical and health sciences ,Percutaneous Coronary Intervention ,0302 clinical medicine ,Risk Factors ,Internal medicine ,medicine ,Humans ,Registries ,030212 general & internal medicine ,Propensity Score ,education ,Aged ,Proportional Hazards Models ,education.field_of_study ,Proportional hazards model ,business.industry ,Hazard ratio ,Percutaneous coronary intervention ,Drug-Eluting Stents ,Middle Aged ,Confidence interval ,Treatment Outcome ,Coronary Occlusion ,Drug-eluting stent ,Chronic Disease ,Conventional PCI ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business - Abstract
Background Chronic total occlusion (CTO) is a challenging entity in coronary interventions. With improvements in technology and techniques, success rates for percutaneous coronary intervention (PCI) of CTO continue to improve. However, the clinical benefits of PCI remain unclear. The aim of the study was to determine the effectiveness of successful PCI on clinical outcomes using drug-eluting stents in patients with CTO. Methods From 2004 to 2010, we analyzed 898 patients with at least one CTO who underwent successful PCI (n = 424, 448 lesions) or only medical treatment (n = 474, 519 lesions) from a multicenter registry. The primary outcome was all-cause death. Results During a median of 2.2 years, incidence rate of all-cause death after successful PCI was lower than that after medical treatment (10.6% and 17.5%, p = 0.004). However, the multivariate Cox proportional hazards model showed that successful PCI was not associated with improvement in mortality compared to medical treatment [adjusted hazard ratio (HR) 0.84, 95% confidence interval (CI) 0.57–1.24, p = 0.38]. Comparable results were obtained after propensity-score matching. Subgroup analysis of propensity-score matched population demonstrated that patients with age under 65 years benefited from successful PCI (HR 0.25, 95% CI 0.08–0.75, p for interaction = 0.005). Conclusions In patients considered for CTO intervention, medical treatment appears to be associated with a similar mortality compared to successful PCI. Successful CTO PCI might be associated with survival benefit in younger patients compared to medical treatment. more...
- Published
- 2019
- Full Text
- View/download PDF
42. Impact of multi-vessel vasospastic angina on cardiovascular outcome
- Author
-
Hyeon Cheol Gwon, Sang Hong Baek, Hyuck Moon Kwon, Youngkeun Ahn, Byoung Kwon Lee, Dong-Soo Kim, Seung-Woon Rha, Sang Ho Jo, Dong-Ju Choi, Jung-Won Suh, Tae Hyun Yang, Kwang Pil Ko, Keun Ho Park, Seung Hwan Han, Kwan Yong Lee, and Sung Ho Her more...
- Subjects
Adult ,Male ,0301 basic medicine ,medicine.medical_specialty ,Acute coronary syndrome ,Single vessel ,Coronary Vasospasm ,030204 cardiovascular system & hematology ,Coronary Angiography ,Risk Assessment ,Angina Pectoris ,New onset ,Coronary artery disease ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Cause of Death ,Internal medicine ,Republic of Korea ,parasitic diseases ,Prevalence ,medicine ,Humans ,Registries ,Aged ,Vasospastic angina ,Medical treatment ,business.industry ,Arrhythmias, Cardiac ,Vasospasm ,Middle Aged ,Prognosis ,medicine.disease ,030104 developmental biology ,Baseline characteristics ,cardiovascular system ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business - Abstract
Since clinical characteristics and prognosis of patients with multi-vessel vasospastic angina (VSA) are not clear, we investigated the nature and prognosis of multi-vessel VSA in Koreans.Among 2960 patients enrolled in the VA-KOREA (Vasospastic Angina in Korea) registry, 104 definite multi-vessel VSA patients, 163 single vessel VSA patients and 737 non-VSA patients were identified using the intracoronary ergonovine provocation test.Multi-vessel VSA and single vessel VSA groups showed similar baseline characteristics and medical treatment on discharge, but different from the non-VSA group. The primary composite endpoint (cardiac death, acute coronary syndrome, and symptomatic new onset arrhythmia) over a 36-month follow-up period was significantly higher in the multi-vessel VSA group than in the single vessel VSA and non-VSA groups (8.7% vs. 1.8% and 1.1%, each log-rank p 0.05, respectively). The rate of death and acute coronary syndrome of the multi-vessel VSA group was higher than in the single vessel VSA and non-VSA groups (5.8% vs. 1.2% and 0.9%, each log-rank p 0.05, respectively). In addition, multi-vessel VSA was an independent predictor of the primary composite endpoint at 36 months (HR 8.5, 95% CI [2.6-27.2], p0.0001).Patients with multi-vessel VSA had worse clinical outcomes than single vessel VSA and non-VSA groups, suggesting that the existence of multi-vessel VSA itself is highly prognostic. more...
- Published
- 2019
- Full Text
- View/download PDF
43. Comparison of Resolute zotarolimus-eluting and Xience everolimus-eluting stents in patients with de novo long coronary artery lesions
- Author
-
Myung Ho Jeong, Yun-Seok Choi, Jang Hyun Cho, Young-Hak Kim, Bong-Ki Lee, Seung-Woon Rha, Weon Kim, Seung-Whan Lee, Jung-Min Ahn, Hun Sik Park, Joo Young Yang, Seong Wook Park, Do Yoon Kang, Cheol Hyun Lee, Seung-Jung Park, Chang-Wook Nam, Pil Hyung Lee, Sung Ho Her, and Duk-Woo Park more...
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Everolimus eluting stent ,Coronary Artery Disease ,030204 cardiovascular system & hematology ,Coronary Angiography ,Prosthesis Design ,law.invention ,03 medical and health sciences ,Percutaneous Coronary Intervention ,0302 clinical medicine ,Randomized controlled trial ,Risk Factors ,law ,Internal medicine ,Angioplasty ,medicine ,Humans ,Single-Blind Method ,Zotarolimus ,In patient ,Everolimus ,Prospective Studies ,cardiovascular diseases ,030212 general & internal medicine ,Aged ,Sirolimus ,business.industry ,Follow up studies ,Stent ,Drug-Eluting Stents ,General Medicine ,equipment and supplies ,Coronary Vessels ,Treatment Outcome ,surgical procedures, operative ,medicine.anatomical_structure ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business ,Immunosuppressive Agents ,Follow-Up Studies ,medicine.drug ,Artery - Abstract
Outcomes for stent-based coronary intervention of lesions with long diseased segments remain relatively unfavorable. This study sought to compare the efficacy of Resolute zotarolimus-eluting stents (R-ZES) and Xience everolimus-eluting stents (EES) for very long coronary lesions.This randomized, multicenter, prospective trial compared the use of R-ZES with EES for very long (≥50 mm) native coronary lesions. The primary end point was in-segment late luminal loss at 12-month angiographic follow-up. A total of 400 patients were needed to assess the primary end point. However, owing to very slow enrollment of patients, this trial was early terminated (302 patients were enrolled), and thus, this report provides descriptive information on primary and secondary end points. The R-ZES and EES groups had similar baseline characteristics. Lesion length was 49.6±10.2 and 50.6±13.3 mm in the R-ZES and EES groups, respectively (P=0.47). The number of stents used at the target lesion was 2.1±0.3 and 2.2±0.5, respectively. Twelve-month angiographic follow-up was performed in 50% of eligible patients. In-segment late luminal loss did not significantly differ between the R-ZES and EES groups (0.17±0.57 vs. 0.09±0.43 mm, P=0.32). In-segment binary restenosis rates were 8.1 and 5.3% in the R-ZES and EES groups, respectively (P=0.49). There were no significant between-group differences in the rate of adverse events (death, myocardial infarction, stent thrombosis, target lesion revascularization, and composite outcomes).For patients with very long native coronary artery disease, R-ZES and EES implantation showed comparable angiographic and clinical outcomes through 1 year of follow-up. more...
- Published
- 2019
- Full Text
- View/download PDF
44. Influence of preprocedural glycemic control on clinical outcomes of endovascular therapy in diabetic patients with lower extremity artery disease: an analysis from a Korean multicenter retrospective registry cohort
- Author
-
Jae-Hwan Lee, Jung-Hee Lee, Sang Rok Lee, Young Jin Choi, Hoyoun Won, Hyun Kim, Cheol Woong Yu, Sang Cheol Jo, Seung-Whan Lee, Jung-Joon Cha, Chang Hwan Yoon, Sung Kee Ryu, Pil-Ki Min, Yu Jeong Choi, Weon Kim, Ju Han Kim, Sung Ho Her, Donghoon Choi, Byung Hee Hwang, Ae Young Her, Sang-Ho Park, Jang Hwan Bae, Yoon Seok Koh, Yun Hyeong Cho, Su Hyun Kim, Young Guk Ko, Jung-Kyu Han, Seung-Hyuk Choi, Sanghoon Shin, Hyoeun Kim, Woo-Young Chung, In Ho Chae, Woong Chol Kang, Ju Yeol Baek, and Young Jin Yoon more...
- Subjects
Blood Glucose ,Male ,medicine.medical_specialty ,lcsh:Diseases of the circulatory (Cardiovascular) system ,Time Factors ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Risk Assessment ,Amputation, Surgical ,Peripheral Arterial Disease ,Diabetes mellitus ,Risk Factors ,Internal medicine ,Clinical outcomes ,Republic of Korea ,Glucose control ,medicine ,Humans ,Hypoglycemic Agents ,Endovascular treatment ,Registries ,Glycemic ,Angiology ,Aged ,Retrospective Studies ,Original Investigation ,Glycated Hemoglobin ,Peripheral artery disease ,Proportional hazards model ,business.industry ,Incidence (epidemiology) ,Endovascular Procedures ,Middle Aged ,medicine.disease ,Limb Salvage ,Intermittent claudication ,Treatment Outcome ,Amputation ,Lower Extremity ,lcsh:RC666-701 ,Glycated hemoglobin A ,Cohort ,Female ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,Biomarkers - Abstract
Background The influence of intensive glucose control in diabetic patients on the macrovascular outcomes is controversial. Thus, this study aimed to elucidate the effect of preprocedural hemoglobin A1c (HbA1c) on clinical outcomes after endovascular therapy for lower extremity artery disease (LEAD) in diabetic patients. Methods Diabetic patients were enrolled from the retrospective cohorts of a Korean multicenter endovascular therapy registry and were divided according to the HbA1c level during index admission into the optimal ( Results Of the 1103 patients enrolled (897 men, mean age 68.2 ± 8.9 years), 432 (39.2%) were classified into the optimal glycemic control group and 671 (60.8%) into the suboptimal glycemic control group. In-hospital events and immediate procedural complications were not different between the two groups. The suboptimal group showed a trend towards a higher incidence of MALE than the optimal group (log-rank p = 0.072). Although no significant differences were found between the two groups in terms of overall survival or amputation, the risk of reintervention was significantly higher in the suboptimal group (log-rank p = 0.048). In the multivariate Cox regression model, suboptimal glycemic control was one of the independent predictors for reintervention. When our data were analyzed according to the initial presentation, suboptimal preprocedural HbA1c significantly increased the incidence of MALE compared with optimal preprocedural HbA1c only in patients with intermittent claudication. Conclusion In diabetic patients undergoing endovascular therapy for LEAD, suboptimal preprocedural HbA1c is associated with an increased risk of adverse limb events, especially in patients with intermittent claudication. Further prospective research will be required to validate the role of more intensive glycemic control on the reduction of adverse limb events in diabetic patients undergoing endovascular therapy for LEAD. more...
- Published
- 2020
45. Comparison of drug-eluting stents and drug-coated balloon for the treatment of drug-eluting coronary stent restenosis: A randomized RESTORE trial
- Author
-
Duk-Woo Park, Woo-Young Chung, Soo Jin Kang, Pil Hyung Lee, Seung-Woon Rha, Seong Wook Park, Seung-Jung Park, Yiu Tung Anthony Wong, Moo Hyun Kim, Do Yoon Kang, Young Joon Hong, Seung-Whan Lee, Jung-Min Ahn, Eun-Seok Shin, Sung Ho Her, Chang-Wook Nam, Cheol Hyun Lee, Young-Hak Kim, Jin Bae Lee, and Cheol Whan Lee more...
- Subjects
medicine.medical_specialty ,Everolimus ,business.industry ,medicine.medical_treatment ,Stent ,030204 cardiovascular system & hematology ,medicine.disease ,Balloon ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,Restenosis ,law ,Angioplasty ,Internal medicine ,Coronary stent ,medicine ,Cardiology ,030212 general & internal medicine ,Myocardial infarction ,Cardiology and Cardiovascular Medicine ,business ,Nuclear medicine ,medicine.drug - Abstract
Background This study sought to evaluate the optimal treatment for in-stent restenosis (ISR) of drug-eluting stents (DESs). Methods This is a prospective, multicenter, open-label, randomized study comparing the use of drug-eluting balloon (DEB) versus second-generation everolimus-eluting stent for the treatment of DES ISR. The primary end point was in-segment late loss at 9-month routine angiographic follow-up. Results A total of 172 patients were enrolled, and 74 (43.0%) patients underwent the angiographic follow-up. The primary end point was not different between the 2 treatment groups (DEB group 0.15 ± 0.49 mm vs DES group 0.19 ± 0.41 mm, P = .54). The secondary end points of in-segment minimal luminal diameter (MLD) (1.80 ± 0.69 mm vs 2.09 ± 0.46 mm, P = .03), in-stent MLD (1.90 ± 0.71 mm vs 2.29 ± 0.48 mm, P = .005), in-segment percent diameter stenosis (34% ± 21% vs 26% ± 15%, P = .05), and in-stent percent diameter stenosis (33% ± 21% vs 21% ± 15%, P = .002) were more favorable in the DES group. The composite of death, myocardial infarction, or target lesion revascularization at 1 year was comparable between the 2 groups (DEB group 7.0% vs DES group 4.7%, P = .51). Conclusions Treatment of DES ISR using DEB or second-generation DES did not differ in terms of late loss at 9-month angiographic follow-up, whereas DES showed better angiographic results regarding minimal MLD and percent diameter stenosis. Both treatment strategies were safe and effective up to 1 year after the procedure. more...
- Published
- 2018
- Full Text
- View/download PDF
46. Clinical implications of combined glucose intolerance in treatment-naïve hypertensive patients
- Author
-
Kiyuk Chang, Beom-June Kwon, Tai-Ho Rho, Ha Wook Park, Ki-Bae Seung, Wook-Sung Chung, Dae-Won Kim, Mahn-Won Park, and Sung-Ho Her
- Subjects
Adult ,Blood Glucose ,Male ,medicine.medical_specialty ,Ambulatory blood pressure ,Physiology ,Blood Pressure ,Pulse Wave Analysis ,030204 cardiovascular system & hematology ,Gastroenterology ,Therapy naive ,03 medical and health sciences ,Sex Factors ,Vascular Stiffness ,0302 clinical medicine ,Central blood pressure ,Internal medicine ,Glucose Intolerance ,Internal Medicine ,medicine ,Humans ,Clinical significance ,030212 general & internal medicine ,Normal glucose tolerance ,Anthropometry ,business.industry ,Fasting ,General Medicine ,Blood Pressure Monitoring, Ambulatory ,Glucose Tolerance Test ,Middle Aged ,Postprandial Period ,medicine.disease ,Postprandial ,Echocardiography ,Hypertension ,Arterial stiffness ,Female ,business ,hormones, hormone substitutes, and hormone antagonists - Abstract
This study is the first study to evaluate clinical significance of combined glucose intolerance (CGI) in treatment-naïve hypertensive patients.We compared the results of demographic, anthropometric, clinical, laboratory examinations, echocardiography, arterial stiffness, central blood pressure (BP) and ambulatory BP monitoring (ABPM) between the groups according to fasting blood sugar (FBS), postprandial 2 hour blood glucose (PP2) and gender in treatment-naïve hypertensive patients. A total of 376 concecutively-eligible patients were categorized as follows: (1) normal glucose tolerance (NGT); FBS100 mg/dL and PP2140 (2) isolated glucose intolerance (IGI); 100≤FBS126 or 140≤PP2200, but not both 100≤FBS126 and 140≤PP2200 (3) CGI; both 100≤FBS126 and 140≤PP2200.Males were divided into NGT (n = 58, 33.1%), IGI (n = 88, 50.3%), CGI (n = 29, 16.6%) and females were divided into NGT (n = 59, 43.1%), IGI (n = 48, 35%), CGI (n = 30, 21.9%). In males multivariate analyses revealed that mitral average E/Ea (IGI vs CGI, p = 0.022), brachial-ankle pulse wave velocity baPWV(Rt.) (IGI vs CGI, p = 0.026), baPWV(Lt.) (IGI vs CGI, p = 0.018), office systolic BP (SBP) (NGT vs. CGI, p = 0.005; IGI vs. CGI, p = 0.001), office diastolic BP (DBP) (NGT vs. CGI, p = 0.034; IGI vs. CGI, p = 0.019), night-time SBP (NGT vs. CGI, p = 0.049; IGI vs. CGI, p = 0.018) were significantly higher in the CGI group than in the NGT or IGI group. However, there were no significant differences between the female groups.Treatment-naïve hypertensive males with CGI revealed subclinical diastolic dysfunction, arterial stiffness, and BPs. more...
- Published
- 2018
- Full Text
- View/download PDF
47. Comparison of 1-Year Outcomes of Triple (Aspirin + Clopidogrel + Cilostazol) Versus Dual Antiplatelet Therapy (Aspirin + Clopidogrel + Placebo) After Implantation of Second-Generation Drug-Eluting Stents into One or More Coronary Arteries: from the DECREASE-PCI Trial
- Author
-
Jae-Hwan Lee, Duk-Woo Park, Jae Bin Seo, Si Wan Choi, Cheol Whan Lee, Seong Wook Park, Pil-Ki Min, Cheol Hyun Lee, Seung-Whan Lee, Pil Hyung Lee, Jung-Min Ahn, Sung Ho Her, Youngjin Choi, Gyung Min Park, Jang Hyun Cho, Seung-Jung Park, Soo Jin Kang, Young-Hak Kim, Chang-Wook Nam, Jong-Young Lee, Won-Yong Shin, and Hyun-Sook Kim more...
- Subjects
Male ,medicine.medical_specialty ,Endpoint Determination ,medicine.medical_treatment ,Myocardial Infarction ,Coronary Artery Disease ,030204 cardiovascular system & hematology ,Coronary Angiography ,Coronary artery disease ,03 medical and health sciences ,Percutaneous Coronary Intervention ,0302 clinical medicine ,Double-Blind Method ,Internal medicine ,Republic of Korea ,Myocardial Revascularization ,medicine ,Humans ,Prospective Studies ,cardiovascular diseases ,030212 general & internal medicine ,Myocardial infarction ,Stroke ,Aspirin ,business.industry ,Percutaneous coronary intervention ,Drug-Eluting Stents ,Middle Aged ,medicine.disease ,Clopidogrel ,Cilostazol ,Survival Rate ,Treatment Outcome ,Cardiology ,Platelet aggregation inhibitor ,Drug Therapy, Combination ,Female ,Cardiology and Cardiovascular Medicine ,business ,Immunosuppressive Agents ,Platelet Aggregation Inhibitors ,medicine.drug - Abstract
This study sought to evaluate the impact of triple antiplatelet therapy on clinical outcomes in patients treated with second-generation drug-eluting stents (DES) for coronary artery disease. There are limited data regarding the impact of triple antiplatelet therapy in patients who underwent implantation of second-generation DES. We planned to randomly assign 2,110 patients treated with second-generation DES to triple (aspirin, clopidogrel, and cilostazol) and dual (aspirin, clopidogrel, and placebo) antiplatelet therapy groups. The primary end point was a composite of death, myocardial infarction, ischemic stroke, or target vessel revascularization (TVR) at 1 year since randomization. The study was stopped early owing to slow enrollment. In total, 404 patients (202 patients each in the triple and dual antiplatelet therapy groups) were finally enrolled. At 1 year, the primary end point had occurred in 3.6% and 9.4% of patients in the triple and dual antiplatelet therapy groups, respectively (hazard ratio [HR] of the triple group 0.396; 95% confidence interval [CI] 0.166 to 0.949; p = 0.038). There was no significant difference between the 2 groups regarding the occurrence of a composite of all-cause death, myocardial infarction, or ischemic stroke (HR 0.583; 95% CI 0.229 to 1.481; p = 0.256). However, the rates of TVR were significantly lower in the triple antiplatelet therapy group than in the dual antiplatelet therapy group (HR 0.118; 95% CI 0.015 to 0.930; p = 0.043). In conclusion, triple antiplatelet therapy with cilostazol after implantation of second-generation DES improved clinical outcomes, mainly by reducing TVR. more...
- Published
- 2018
- Full Text
- View/download PDF
48. Recurrent fetal postpartum stress induced cardiomyopathy after normal vaginal delivery
- Author
-
Yong-Sun Noh, Sung-Ho Her, Chan Joon Kim, Jong Bum Kwon, and Tae-Seok Kim
- Subjects
03 medical and health sciences ,Fetus ,medicine.medical_specialty ,0302 clinical medicine ,business.industry ,Obstetrics ,Vaginal delivery ,Medicine ,Stress induced cardiomyopathy ,030212 general & internal medicine ,030204 cardiovascular system & hematology ,business - Abstract
Stress induced cardiomyopathy is a disease that shows a dysfunction of the ventricle, but it can be rapidly reversible. It often occurs in older women primarily who suffers from emotional or physical stress. There are some case reports about postpartum stress induced cardiomyopathy. Most of the patients are recovered naturally within days to weeks. We report a case of a 37 years-old woman, who had experienced postpartum stress induced cardiomyopathy 8 years ago, revisited hospital because of cardiomyopathy after secondary delivery. Herein we report a rare case of recurrent stress induced cardiomyopathy after secondary normal vaginal delivery. more...
- Published
- 2017
- Full Text
- View/download PDF
49. Clinical impact of statin therapy on vasospastic angina: data from a Korea nation-wide cohort study
- Author
-
Sung Ho Her, Min Ho Lee, Sang-Ho Jo, Sang Hong Baek, Sung Seek Cho, Won-Woo Seo, Kwan Yong Lee, Sung Eun Kim, and Seung Hwan Han
- Subjects
Adult ,Male ,medicine.medical_specialty ,Acute coronary syndrome ,Statin ,Time Factors ,medicine.drug_class ,Coronary Vasospasm ,030204 cardiovascular system & hematology ,Risk Assessment ,Angina Pectoris ,Angina ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,parasitic diseases ,Republic of Korea ,medicine ,Humans ,Cumulative incidence ,cardiovascular diseases ,030212 general & internal medicine ,Prospective Studies ,Registries ,Acute Coronary Syndrome ,Aged ,Proportional hazards model ,business.industry ,nutritional and metabolic diseases ,Arrhythmias, Cardiac ,Middle Aged ,medicine.disease ,Treatment Outcome ,Heart Disease Risk Factors ,Cohort ,Propensity score matching ,lipids (amino acids, peptides, and proteins) ,Female ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Cardiology and Cardiovascular Medicine ,business ,Cohort study - Abstract
The effect of statin therapy on reducing adverse cardiovascular events in vasospastic angina (VSA) has been inconsistent. Therefore, we investigated the association between statin therapy and adverse cardiovascular events in a large, prospective VSA cohort. The Variant Angina Korea registry consecutively enrolled 2960 patients suspected VSA. Among them, we included 1713 patients who were diagnosed with VSA based on coronary provocation test. We divided the patients into the statin (n = 744) and no-statin group (n = 914) according to the medication prescribed at discharge. The primary outcome was a composite of cardiac death, acute coronary syndrome, and new-onset life-threatening arrhythmia during a 3-year follow-up period. The primary outcome occurred in 32 patients (4.3%) in the statin and 28 patients (3.1%) in the no-statin group. In Kaplan–Meier analysis before and after propensity score matching, there was no significant difference in the cumulative incidence of primary outcomes between both groups. Multivariate Cox regression analysis demonstrated that the focal type of VSA was independent predictor of primary outcomes, but statin therapy was not. Furthermore, the lack of benefit of statin therapy for primary outcomes was consistently observed across the statin intensity and spasm characteristics. In conclusion, the present study demonstrated that statin therapy did not reduce adverse cardiovascular events in patients with VSA. more...
- Published
- 2019
50. Technical Feasibility and Safety of Percutaneous Coronary Intervention for True Ostial Left Anterior Descending Artery-Chronic Total Occlusion
- Author
-
Jae-Hyung Roh, Seung-Whan Lee, Taek Kyu Park, Pil Hyung Lee, Sang Yong Yoo, Young Joon Hong, Chang Hwan Yoon, Young Rak Cho, Cheol Hyun Lee, Jae-Hwan Lee, Jang Hoon Lee, Yong Hoon Yoon, Kook Jin Chun, Jon Suh, Jong-Young Lee, and Sung Ho Her more...
- Subjects
Male ,medicine.medical_specialty ,Time Factors ,medicine.medical_treatment ,Dissection (medical) ,030204 cardiovascular system & hematology ,Coronary Angiography ,03 medical and health sciences ,0302 clinical medicine ,Hematoma ,Percutaneous Coronary Intervention ,Internal medicine ,Intravascular ultrasound ,medicine ,Humans ,cardiovascular diseases ,030212 general & internal medicine ,Myocardial infarction ,Retrospective Studies ,medicine.diagnostic_test ,business.industry ,Percutaneous coronary intervention ,Middle Aged ,medicine.disease ,Coronary Vessels ,medicine.anatomical_structure ,Treatment Outcome ,Coronary Occlusion ,Conventional PCI ,Chronic Disease ,cardiovascular system ,Cardiology ,Feasibility Studies ,Female ,Stents ,Cardiology and Cardiovascular Medicine ,business ,TIMI ,Artery ,Follow-Up Studies - Abstract
Structured Abstract Background Percutaneous coronary intervention (PCI) for true ostial left anterior descending artery (LAD)-chronic total occlusion (CTO) lesions poses technical challenges owing to its inherent anatomical features. Methods In total, 270 consecutive patients who underwent PCI for ostial LAD-CTO at 13 major cardiac centers in South Korea were included. Ostial LAD-CTO was strictly defined as a LAD-CTO lesion the proximal cap of which was confined within 1 mm from the carina of the distal left main coronary artery (LMCA) bifurcation. Results Ostial LAD-CTOs were frequently accompanied by stumpless lesion entry (43.4%), whereas significant bending within the occluded segment was less frequent (14.4%). The overall technical success rate was 85.9%, and serious in-hospital adverse events occurred in 5.6%. The retrograde approach tended to contribute more frequently to success in patients with concomitant LMCA disease, stumpless CTO, interventional collaterals, and higher Japanese-CTO scores. Apparent dissection or hematoma requiring rescue procedure at the LMCA or left circumflex artery occurred in 14 patients (5.2%), with a higher tendency in patients who had LMCA disease (12.1% vs. 4.2%) and stumpless entry (9.4% vs. 2.0%) than in those without. Among patients who were successfully treated with an average number of 1.7 stents, target-vessel failure occurred in 23 patients (9.9%) during a median 3.3 years of follow-up. Conclusions In this first, large-scale analysis of true ostial LAD-CTO, PCI was feasible with a high technical success rate and favorable mid-term outcomes. Clinically relevant inflow vessel injury can occur during PCI and should be an important technical consideration regarding safety. more...
- Published
- 2019
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.